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ABSTRACT OF DISSERTATION 
 
 
 
ROLE OF VIRAL AND HOST FACTORS IN INFLUENZA VIRUS MEDIATED 
INHIBITION OF INTERLEUKIN-23 
 
 Influenza virus is one of the major respiratory pathogens of humans as well as 
animals, including equines. There is an increasing evidence that bacterial infections are the 
most common cause of the death during influenza. In horses also, secondary bacterial 
pneumonia can lead to death, and surviving horses may take up to six months for the 
complete recovery resulting in heavy economic loss to the equine industry. Interleukin 
(IL)-23 mediated innate immune response has been shown to protect the host from various 
respiratory bacterial infections. However, studies to investigate the role of host and viral 
factors in the regulation of IL-23 are limited.  Endoplasmic reticulum (ER) stress-induced 
transcription factor CHOP-10 and IFN-β has been shown to participate in the regulation of 
IL-23. Primary hypothesis for the current study was that influenza A virus (IAV) NS1 
protein downregulates the IL-23 expression via inhibition of CHOP-10. In order to test our 
hypothesis, we infected the RAW264.7 cells - a murine macrophage cell line, and primary 
murine alveolar macrophage cells either with the wild type Influenza A virus (PR/8/34, 
PR8) or isogenic mutant virus lacking NS1 (delNS1). Quantitative analysis of mRNA 
expression revealed a significantly higher mRNA expression of IL23p19, IFN-β and 
CHOP-10 in delNS1 virus infected cells as compared the PR8 virus infected cells. 
Additionally, overexpression of CHOP-10 partially restored the expression of IL-23p19 in 
PR8 virus infected cells and knockdown of CHOP-10 resulted in downregulated expression 
of IL-23p19 in delNS1 infected cells. Taken together, these results suggest that IAV NS1 
protein mediated inhibition of CHOP-10 expression leads to downregulation of IL-23 
expression in macrophage cells in-vitro. Similar results were also observed in-vivo using 
IAV and Streptococcus zoooepidemicus (S. ze) co-infection model. In a co-infection mouse 
model delNS1 virus co-infection resulted in significantly higher expression of the IL-23 
and IL-17. Considering the role of IL-23 in protection against respiratory bacterial 
pathogens, effect of exogenous supplementation of IL-23 was also investigated in the 
influenza and S. ze co-infection mouse model. We found that a single intranasal dose of 
recombinant murine IL-23 significantly improved the survival of mice co-infected with 
PR8 and S .ze. Overall, our study suggests that IAV infection subverts the IL-23 mediated 
respiratory innate immune response and restoration of IL-23 could protect from influenza-
associated respiratory bacterial infections.
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CHAPTER 1 
Introduction and hypothesis 
1.1. Introduction 
Influenza is one of the most common viral respiratory disease of birds, humans, and 
animals including horses and is caused by influenza A virus (IAV).  Each year, recurrent 
epidemics of influenza, commonly called seasonal influenza, result in 3-5 million severe 
cases and 250,000-500,000 deaths worldwide, leading to significant economic losses. 
Occasional pandemics further add to the quandary. Secondary bacterial infections were 
suggested to be major contributors in the pathology and mortality associated with human 
influenza almost a century ago and confirmed later [1]. Similarly, secondary bacterial 
infections are not uncommon in equine influenza. Despite significant progress in 
understanding the pathogenesis of influenza and the mechanism of influenza and bacterial 
synergy, bacterial co-infections still remain the major factor in determining the outcome of 
influenza. Therefore, the current study was designed to explore the possible mechanism 
that could contribute to increased susceptibility to secondary bacterial infection during 
influenza.   
 The first hypothesis was that influenza virus mediated inhibition of IL-23 leads to 
enhance susceptibility of the host to secondary bacterial infections. Cytokines are integral 
parts of the innate immune system, a broadly reactive defense mechanism which acts as 
the first line of defense against a variety of invading pathogens. Interleukin (IL)-23 is a 
recently identified cytokine that has been shown to be important in the respiratory innate 
immune response. Interleukin (IL)-23, in concert with IL-17, constitutes a newly identified 
innate immune pathway. The host IL-23/IL-17 pathway has been shown to play a critical 
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role in the clearance of many respiratory bacterial pathogens [2]. However, its role during 
influenza and bacterial co-infection has not been investigated. Thus, it was hypothesized 
that inhibition of respiratory IL23/IL17 pathway by influenza virus predisposes the host to 
secondary bacterial infection.   
 The second hypothesis was that influenza virus inhibits the expression of 
endoplasmic reticulum (ER) stress induced transcription factors. ER stress response, also 
called the unfolded protein response (UPR), is an evolutionary molecular cascade to 
maintain ER homeostasis and the protein folding capacity of the ER. However, recent 
studies implicate the ER stress response in other cellular and disease processes such as 
apoptosis and inflammation [3].  Since viruses rely heavily on the host cell protein 
synthesis machinery, the functional status of the ER may significantly affect viral 
replication and pathogenesis. Differential activation of ER stress pathways has been shown 
for multiple viruses including influenza. However, viral factors responsible for differential 
activation of ER stress response in influenza-infected cells are not known. C/EBP 
homologous protein-10 (CHOP-10) is one of the key mediators of ER stress. During 
prolonged ER stress, CHOP-10 mediates cell death by apoptosis. Although apoptosis could 
help in the pathogenesis of the virus, it could also prematurely terminate viral replication. 
CHOP-10 also acts as a transcription factor for several other genes. In human dendritic 
cells (DCs), induction of CHOP-10 was critical in IL-23 expression [4]. Therefore, it was 
hypothesized that influenza virus inhibits the CHOP-10. 
 The next hypothesis for the study was that influenza virus NS1 protein was the viral 
factor that mediates the inhibition of CHOP-10. In order to reduce the protein load during 
ER stress, eukaryotic initiation factor-2 alpha (eIF2-α) is phosphorylated to shut down 
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global protein synthesis in the cell. Two major cellular kinases, double-stranded-RNA 
(dsRNA)-activated protein kinase (PKR) and PKR-like ER kinase (PERK), are important 
in the phosphorylation of eIF2-α. Influenza virus NS1 is known to inhibit PKR that also 
results in inhibition of type-I interferons (IFN). Additionally, influenza virus infection has 
been found to not to activate PERK. Phosphorylation of eIF2-α, also leads to selective 
transcription of activating transcription factor 4 (ATF4) that leads to induction of CHOP-
10. Inhibition of the kinases thus may favor influenza virus replication in two ways- I) by 
allowing viral proteins to be synthesized before the IFN response shuts down cellular 
protein synthesis; II) by delaying the onset of apoptosis induced by the endoplasmic 
reticulum (ER) stress-induced transcription factor CHOP-10. Therefore, it was 
hypothesized that influenza virus NS1 inhibits the expression of CHOP-10. 
1.2. Hypothesis  
Influenza virus NS1 protein mediated inhibition of CHOP-10 leads to an impaired 
IL-23/IL-17 immune pathway in the lungs and causes increased susceptibility to secondary 
bacterial infections.  
1.3. Research objectives 
 In order to test the above hypothesis the study is performed with following objectives   
1. Determine the effect of influenza virus on ER stress  
2. Determine the effect of NS1 mediated CHOP-10 inhibition on IL-23 
expression  
3. Determine the effect of restoration of respiratory IL-23 on pathogenesis of 
influenza 
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 Macrophages are important components of host innate immune defense. Besides 
DCs, macrophage cells are the only cells that secrete biologically active IL-23 [5]. 
Therefore, the hypothesis was tested in macrophage cells in vitro and in a mouse model in 
vivo. The overreaching goal of the study was to investigate role of the IL-23/IL-17 pathway 
in the horse. However, a mouse model for influenza as well as co-infection has been well 
established using the PR8 virus. Although there are areas that need further investigation, 
results of this dissertation provide evidence to support the major hypotheses. Secondary 
bacterial infections, similar to human influenza, are also common in equine influenza and 
it is possible that IL-23/IL17 pathway could be a general mechanism that leads to increased 
susceptibility during influenza and these results could be applied to equine influenza. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Ashish Tiwari 2014 
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CHAPTER 2 
Literature review 
Influenza viruses are negative-sense single-stranded, segmented RNA genome 
viruses of family Orthomyxoviridae. The family Orthomyxoviridae consists of five, well-
characterized genera, including    Influenzavirus  A, Influenzavirus B, Influenzavirus  C, 
Isavirus and Thogotovirus, and recently discovered, still undescribed, sixth genus [6]. Each 
genus of influenza virus has one species or type - Influenza A virus, Influenza B virus and 
Influenza C virus, respectively. These three genera can be distinguished by antigenic 
differences in their nucleoprotein and matrix protein. Among the three types, only 
influenza A viruses (IAV) are further subtyped based on their surface glycoproteins 
hemagglutinin (HA) and neuraminidase (NA). All three influenza viruses can infect 
mammals. Whereas influenza B viruses have been shown to infect humans and seals and 
influenza C viruses infect human and pigs, IAVs can infect various mammals including 
equine. 
2.1. Influenza A virus 
IAV is the primary etiological agent of a highly contagious, acute respiratory 
disease of humans and animals that follows recurring seasonal epidemics of high morbidity 
and mortality, as well as worldwide pandemics. On the basis of two surface glycoproteins-
HA and NA- influenza a viruses have been further subtyped into 16 well established HA 
subtypes and 9 NA subtype [7]. Recently, a 17th HA subtype has been identified from little 
yellow-shouldered bats captured at two locations in Guatemala. However, attempts of virus 
isolation in either cell culture or chicken embryos were unsuccessful [8]. Wild aquatic bird 
such as- waterfowl, duck, geese, swan, gulls, terns, etc. - are the natural reservoirs for all 
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the subtypes of IAV. In the wild aquatic birds, the virus is benignly adapted and does not 
cause symptomatic infection. In these reservoir hosts, virus is considered to be in an 
evolutionary stasis that establishes a perpetual viral gene pool. Different subtypes of IAV, 
however, have successfully jumped from their natural reservoir hosts to other avian and 
mammalian hosts and caused clinical disease [9].  
2.2. Viral genome and encoded proteins 
The genome of influenza virus is about 13.6 kb and consists of eight single-
stranded, negative-sense RNA molecules. Each RNA segment is encapsidated with several 
nucleocapsid protein (NP) molecules forming a flexible rod-shaped ribonucleoprotein 
(RNP) that also has three viral polymerase protein- basic polymerase 1(PB1), basic 
polymerase 2 (PB2) and acidic polymerase (PA)- associated at the end of RNP [10]. The 
eight genome segments of influenza virus encode for the ten proteins of influenza virus 
(HA, NA, PB1, PB2, PA, NP, NS1, NS2, M1 and M2) that are found in all IAV. In addition 
to PB1, gene segment 2 also encodes another protein PB1-F2 that localizes to mitochondria 
and has been implicated in cellular apoptosis. Recently, an additional protein N40, an N-
terminal truncated version of PB1, was discovered to be translated from fifth AUG codon 
(codon 40) of PB1 [11]. In 2012, PA-X, another new protein of IAV, was discovered which 
is synthesized from segment three that primarily encodes PA [12].  
2.2.1. The surface glycoproteins 
Influenza virus encodes two surface glycoproteins-HA and NA that have important 
roles in the host range, viral replication, and pathogenicity. 
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Hemagglutinin (HA) 
 Hemagglutinin is membrane glycoprotein (MW 61.5 kDa monomer) and the major 
surface antigen of influenza virus encoded by the fourth largest gene (1778 nucleotides) of 
the viral genome. The HA molecule is synthesized as homotrimeric spike of non-covalently 
linked monomers in the rough endoplasmic reticulum of the infected cells [13]. Native HA 
is synthesized as a single polypeptide (HA0) that is processed into two disulfide-linked 
subunits referred as HA1 and HA2. Depending on the strain, the cleavage of HA0 is carried 
out either by ubiquitously distributed furin proteases or tissue specific proteases such as 
trypsin [14] and HA cleavage is a crucial determinant of viral pathogenicity [14]. Influenza 
virus HA has two important functions- (I) facilitate viral attachment by binding to sialic 
acid-containing receptors on the host cell, and (II) mediate fusion between the endocytic 
vesicle and viral membrane during penetration, enabling release of the viral genome into 
the cytoplasm. Being a surface antigen, HA is also under constant immune selection 
pressure. Thus, mutations in HA may allow the virus to escape neutralizing antibodies by 
antigenic drift [15].  
Neuraminidase (NA) 
 The NA gene (1461 nucleotides) of influenza virus encodes for neuraminidase 
protein -the second surface glycoprotein of influenza virus. The NA molecule is 
synthesized as a 454 amino acid (aa) monomer that oligomerizes to form a mushroom 
shaped trimeric protein. While the N-terminal stalk of NA anchors it to the viral membrane, 
the box-shaped head contains enzymatic activity to catalyze the cleavage of sialic acid [16]. 
The NA protein-mediated enzymatic cleavage of sialic acid from cell surfaces is critical 
for the release of progeny virus during the viral replication cycle. Additionally, it also 
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removes sialic acid residues from the carbohydrates on viral membrane glycoproteins and 
prevents virus self-aggregation [17]. Although NA does not have any direct role in the 
attachment, NA could also remove mucins and facilitate virus access to the epithelial cells 
[18]. NA has also been implicated in facilitating a secondary bacterial infection that will 
be discussed later in this chapter. 
2.2.2. Polymerase proteins 
The PB1, PB2 and PA proteins together form the polymerase complex of the 
influenza virus that provides RNA-dependent RNA polymerase activity for the virus [19, 
20].The proteins are named on the basis of their isoelectric properties: whereas PB1 and 
PB2 are basic proteins PA is an acidic protein.  
PB1 is a 96.5 kDa basic subunit of the polymerase complex encoded by segment 2 
(2270 nucleotides) and serves as a backbone that can bind to the two other subunits of the 
polymerase complex as well as to NP (SB 18, 19). PB1 is a catalytically active subunit of 
RNA-dependent RNA polymerase that is involved in initiation and elongation of mRNA, 
complementary RNA (cRNA), and genomic RNA, in a sequence-specific manner [21, 22]. 
PB1, by endonucleolytic cleavage of cellular mRNA, also generates capped RNA primers 
for initiation of viral mRNA synthesis [23]. 
The coding region (2275 nucleotides) of genomic RNA segment 1 of influenza 
virus encodes the second basic subunit (PB2) of viral polymerase complex. The PB2 
protein binds to the 5’-cap structure (m7GpppNm) of host cell pre-mRNA, which is later 
cleaved in a process called “cap snatching,” to prime viral mRNA synthesis. 
Encoded by the segment 3 (2150 nucleotide coding region) of the influenza virus 
genome, PA is the third and the only acidic subunit of the viral polymerase complex. When 
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expressed individually, PA demonstrates proteolytic activity that affects co-expressed 
proteins and PA itself [24]. However, its specific roles in viral transcription and replication 
are poorly defined [24-26]. 
2.2.3. Nucleoprotein (NP) 
The NP gene (1565 nucleotides) encodes a highly basic, single-stranded RNA 
binding protein with a molecular weight of 56.1 kDa. Nucleoprotein is the second most 
abundant protein of virion. After synthesis and post-translational phosphorylation in the 
cytoplasm, NP is transported into the nucleus of host cells where it binds to newly 
synthesized viral RNA [27, 28] and provides structural organization to the RNP complex. 
NP also interacts with other viral proteins including the viral polymerase proteins (PB1 and 
PB2) and the matrix proteins (M1) [29-31]. Interaction with cellular proteins such as 
importin –α, F-actin, CRM1, BAT/UAP56 and MX has also been observed. Whereas 
interaction of NP with importin-α, F-actin and CRM1 is critical for intracellular trafficking 
of RNP complexes [32-34], interaction with BAT1/UAP56 and MX protein up- and down- 
regulates viral RNA synthesis, respectively [35, 36]. NP is also a major target of immune 
cells as cytotoxic T lymphocytes non-specifically cross react with NP of all influenza virus 
subtypes [37]. 
2.2.4. Matrix protein 
The M gene (1027 nucleotides) of influenza virus, by alternative splicing of 
overlapping reading frames, encodes two viral structural proteins- matrix protein 1 and 2 
(M1 and M2). M1 is the most abundant protein present underlying the viral envelope. M1 
is also suggested to interact with the cytoplasmic tails of HA and NA molecules [38]. M1 
binds to the RNP through its C-terminal domain to facilitate their nuclear-cytoplasmic 
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transport [39, 40]. It also has critical roles in recruitment and assembly of viral and host 
components for the budding of the virus [41]. M2 protein is a type-III integral membrane 
protein with a short ectodomain, a transmembrane domain, and a cytoplasmic tail [42]. It 
forms a tetrameric proton channel that allows the acidification of the interior of the virion 
from the acidified endosomes leading to critical conformational changes and uncoating of 
the viral RNP complex. Therefore, M2 ion channel blockers have been used as influenza 
virus replication inhibitors.  
2.2.5. Nonstructural proteins 
Segment eight of the influenza viral genome is the smallest gene (890 nucleotides) 
and encodes two nonstructural protein- NS1 and NS2. The NS1 protein has a molecular 
mass of approximately 26 KDa and a strain-specific length of 230-237 aa [43]. However, 
a C-terminal truncated (15-30 aa) NS1 protein also exists in nature [44]. The NS1 protein 
of IAVs can be divided into two distinct functional domains. The N-terminal RNA-binding 
domain (RBD) consist of residues 1-73 that in vitro binds with low affinity  to various 
RNA molecules in a sequence-independent manner [45, 46]. Residues 74-230 of NS1 
protein form the C-terminal effector domain (ED) that mediates interaction with cellular 
proteins of the host, and also helps in stabilization of the RNA-binding domain [47].  
Within host cells, functional NS1 exists as a homodimer stabilized by interaction between 
both the N-terminal RBD and C-terminal ED of NS1 [48].  Homodimerization of the RBD 
is also essential for its RNA binding function. A double-stranded RNA –binding pocket is 
formed by two antiparallel tracks of basic and hydrophilic residues from identical α-helices 
on either side of a deep cleft from two NS1 subunits [49]. Assembly of the dimeric-NS1 
effector domain has not been completely understood. Based on the crystal structure of 
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human NS1 allele A, a strand-strand model that consisted of two NS1 effector domain 
monomers made up of seven β-strands and three α-helices was proposed [50]. In this 
model, each monomer β-sheet forms a crescent shape twisted structure around the central 
α-helix [50]. On the other hand, Hale at al., 2008 [51], proposed a helix-helix model and 
observed that a tryptophan residue located at the interface of monomers was critical for 
dimerization of the effector domain. However, it is important to note that effector domain 
structure published by Hale et al., was for an avian influenza virus allele B NS1, whereas 
the model by Bornholdt and Prasad [50], was based on allele A of NS1 of human influenza 
virus. Hence, it is conceivable that two alleles of NS1 might have a different structure and 
might have a variable effect on pathogenicity of influenza viruses. Also, it should be noted 
that full-length NS1 might have a different conformation, which might impact the functions 
of NS1. To date only two studies are available on the structure of full-length NS1. A crystal 
structure of H5N1 (A/Vietnam/1203/2004) NS1 was determined and it was found that NS1 
forms a dimer through interaction of the RBD and two ED flank the RBD dimers. Also, 
the two domains of NS1 interact separately with respective domains of alternating RBD 
and ED dimers of neighboring NS1 molecules to form a higher-order chain like structure 
[52]. It should be noted, however that H5-NS1 in this study contains a 5aa deletion in the 
linker region and represents only a minority of influenza virus NS1. Recently, Carillo et 
al., determined the structure of full length NS1 from an H6N6 IAV (A/blue-winged 
teal/993/1980) that does not have five aa deletion, and thus may represent more common 
form of NS1[53]. The authors also studied the effect of linker region (LR) mutations on 
the three-dimensional structure of full-length NS1. The study revealed that length of the 
linker, composition of residue 71 and the mechanical hinge are critical determinants in the 
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structure of full-length NS1. Full-length NS1, depending on the strain, can adopt different 
structures. Depending on the orientation of the ED with respect to RBD there could be 
three possible conformations as “open," semi-open and closed conformation that might 
explain some of the strain variation in NS1 functions [53]. Although NS1 is not 
incorporated into the virion, it is abundantly present in virus-infected cells and is one of 
the most versatile protein of influenza virus. NS1 interacts with a variety of cellular 
proteins and plays critical roles in the replication and pathogenesis of influenza virus 
including inhibition of splicing and export of polyadenylated cellular mRNA cellular [54, 
55], promoting translation of viral mRNA [56], and inhibiting cellular innate antiviral 
pathways [57-62]. NS1 protein also inhibits maturation and migration of dendritic cells 
resulting in dysfunctional T-cell stimulation and cytokine production [7]. The functions of 
NS1 will be discussed in detail later in this chapter. 
 Unlike NS1, NS2/NEP (nuclear export protein), expressed from an alternatively 
spliced mRNA of NS RNA segment, is incorporated in the virion in the phosphorylated 
form [63]. NEP, in association with M1, facilitates the transport of viral RNP complex 
from nucleus to the cytoplasm. NS2/NEP is also critical in the regulation of viral RNA 
transcription and replication [64].  
2.3. Replication of influenza virus 
Replication of influenza A viruses is a multistage process that includes attachment, 
entry, fusion and uncoating, genome transcription, viral protein synthesis, assembly and 
finally egress/budding of progeny virions (Figure 2.1).  
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2.3.1. Receptor binding and cell entry 
Influenza virus attaches to sialic acid receptors through HA protein present on the 
surface of the virion. Following receptor binding, virions are endocytosed into a cellular 
compartment. Clathrin-mediated endocytosis is apparently major endocytic mechanism 
[65], however, clathrin- independent mechanisms [66, 67], and macropinocytosis [68, 69] 
has also been proposed for influenza virus internalization.  
2.3.2. Membrane fusion and uncoating 
The acidic pH of endosomal vesicles induces irreversible conformational changes 
in the HA protein that causes the fusion peptide (HA2 subunit) to insert in to the endosomal 
membrane. At this time, the M2 ion channel also facilitates acidification of interior of the 
virus particle that leads to the release of the viral RNP complex. The viral RNP complex 
consists of eight viral RNA segments wrapped around the nucleoprotein together with viral 
polymerases [70]. Subsequently, viral RNP is transported into the nucleus in a process 
mediated by nuclear localization signals on the nucleoprotein [71, 72].  
2.3.3. RNA replication and translation 
The trimeric viral polymerase complex, consisting of PB2, PB1 and PA subunits, 
transcribes viral genomic RNAs in to mRNA by a cap-dependent manner using 5’ cap 
structures derived from host mRNAs. Viral mRNAs derived from viral RNA segments M 
and NS are alternatively spliced to generate M1, M2 and NS1, NEP/NS2, respectively. 
Although host cell machinery performs the splicing, it is most likely regulated by NS1 [73, 
74]. Translation of viral mRNAs is carried out by the host translation machinery, thus, 
during IAV infection, host cell protein synthesis is limited and viral mRNA translation is 
preferred [75-77]. Interaction of NS1 with cellular poly A binding protein II (PABII) [78-
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80] and cleavage and polyadenylation specificity factor subunit 30 (CPSF30) [57, 81] has 
been shown to be important in the inhibition of host mRNA synthesis.  
2.3.4. Virus assembly and release 
Following synthesis in the cytoplasm, viral proteins are transported back to the 
nucleus where viral RNP complexes are formed and then exported out to the cytoplasm 
mediated by M1 [82-84] and NEP/NS2 [85-88]. The ER has an important role in the 
generation of mature influenza virions as it carries out important post translational 
modifications such as glycosylation (HA, NA and M2) and palmitoylation (HA and M2) 
of viral proteins [70]. Virus assembly requires transport of the viral proteins to the plasma 
membrane likely mediated microtubule organizing centers (mTOCS) [89], microtubules 
[89-91] and additional host factor that include coatomer I (COPI) proteins [92](147), Rab 
GTPase (Rab11A)  [93-95] and HIV rev Binding proteins (HRB) [90, 96]. The assembly 
starts by association of HA and NA with lipid rafts at plasma membrane of the host cell 
(152-160). Assembly involves incorporation of eight viral RNP dictated by segment 
specific packaging signals in the viral RNAs (161, 162). The M1   and M2 proteins play 
critical roles in packaging [97, 98]. Viral M2 protein and NA proteins are critical in 
budding and release of the virions. The M2 protein, present in the raft periphery, mediates 
cleavage and particle release [99]. The NA protein cleaves sialic acid from host cells, and 
from the virion glycoproteins that leads to the virion release and prevents virion 
aggregation, respectively [70]. Additionally, the ER serves as an important site of post-
translational modification of influenza viral proteins which could induce ER stress. 
However, functional ER is important in the replication of influenza virus. It is evident that 
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NS1, although not incorporated into the virion, plays critical roles in the regulation of 
influenza virus replication.  
 
 
 
2.4. Host innate defense mechanisms against influenza 
An immunocompetent host during influenza virus infection mounts a robust anti-
viral response to limit viral replication. Both, innate and adaptive immune systems 
participate in containment and clearance of viral infection in about a week. The innate 
immune response, not specific to the pathogen, is however the first and foremost barrier in 
acute influenza infection. An emerging theory is that besides reducing the pathogen burden 
(antiviral resistance), reducing the negative impact of infection on host fitness (disease 
Figure 2.1. Simplified schematic representation of influenza virus replication cycle 
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tolerance) could significantly affect the outcome of infection [100]. While disease 
resistance is important in controlling acute infections, disease tolerance can also protect the 
host from some acute and chronic infections even when resistance mechanisms fail to 
protect the host. In the case of infection of African green monkey and sooty mangabey with 
simian immunodeficiency virus (SIV), for example, despite high viral burden, clinical 
disease does not occur [101]. In the case of influenza and Legionella pneumophila co-
infection impaired ability to tolerate tissue damage resulted in an increased susceptibility 
to bacterial infection; and promoting the tissue repair with amphiregulin treatment resulted 
in increased survival of the host without affecting the pathogen burden [102]. 
Innate immunity against influenza involves a concerted participation of various 
strategies such as physical barriers, soluble factors and immune cells. Pattern recognition 
receptor recognition of viral RNA as a foreign molecule leads to the secretion of type-I 
IFN mainly from macrophages, pneumocytes, conventional DCs and plasmacytoid DCs 
(pDCs) [103-105]. Type-I IFN, in turn, activates hundreds of genes collectively called IFN-
stimulated genes (ISGs), in nearby cells resulting in the antiviral state. Viral infection, in 
addition to type-I IFN, also induces pro-inflammatory cytokine and chemokines. 
Chemokines recruit additional immune cells including neutrophils, monocytes, and natural 
killer (NK) cells to the lungs. Virally infected epithelial cells become the target of NK cells 
that mediate viral clearance [106]. By phagocytizing the virus infected cells, in concert 
with alveolar macrophages, recruited monocytes and neutrophils are an important 
mechanism of viral clearance [107].  
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2.4.1. Physical barriers 
The respiratory epithelium is coated with large amounts of mucins that can trap the 
invading viral or bacterial pathogens. While mucins trap the pathogen, concerted beating 
of the broncho-pulmonary cilia expel the pathogen out of the airway. Loss of this 
mucociliary escalator system is one of the mechanisms of influenza pathogenesis that can 
pre-dispose the host to increased susceptibility to secondary infection [108]. 
2.4.2. Soluble antimicrobial factors 
Pathogens that have successfully compromised the physical barrier are neutralized 
by antimicrobial factors such as lysozymes, lactoferrin, and defensins. In humans, alpha-
defensins, neutrophil produced short cationic peptides, can inhibit the replication of 
influenza virus [109]. Another important soluble factor is the complement system. The 
complement is a heat labile, enzymatic mediator of the innate immune system that helps in 
the clearance of pathogens by increasing the phagocytic clearance of the pathogens. 
Complement present in human serum can neutralize influenza virus and in vivo 
experiments found that in association with natural antibodies (IgM), complement can 
provide protective immunity in influenza naïve hosts [110-112]. Furthermore, complement 
deficient mice were more susceptible to influenza virus infection [113].  
2.4.3. Cytokine and chemokine system 
Cytokines are a diverse family of small proteins that are produced in response to 
different stimuli for intracellular signaling and communicatios. They play an important role 
during viral infections.  Interferons are a type of cytokine that are produced during viral 
infections and are aptly named because of their ability to interfere with viral replication. 
While IFN-α and IFN-ß are type-I IFNs, IFN-γ is often called a type-II IFN.  Although 
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most  nucleated cells can produce the type-I interferons, pDC are considered  as  the  
specialized  producers  of  these  cytokines  [114].  pDCs bind to a common cell surface 
IFN receptors and activate transcription of hundreds of ISGs.  Several protein products of 
ISGs have anti-viral activities. For example, while OAS helps in degradation of viral RNA, 
PKR has an inhibitory effect on viral protein synthesis.  Another ISG protein, Mx is 
associated with resistance against influenza infection [115]. On the other hand, IFN-γ is 
primarily produced by T-cells and NK cells and its function is to activate macrophages. 
Interleukins, produced by leukocytes, are mainly regulators of immune cell differentiation 
and activation. A number of interleukins have been identified so far which can act locally 
or systemically  to  exert  divergent  effects  on  both  innate  and  adaptive  immune  
responses. Chemokines are the largest and fast growing family of cytokines that signal by 
binding to one or more G-protein coupled receptors [116]. Depending upon the spacing of 
their first two cysteine residues, chemokines are classified into four types (CXC, CC, C, 
and CX3C). Chemokines function as chemoattractants to control the migration of cells, 
particularly those of the immune system, and contribute to innate and adaptive immunity 
[117]. Influenza virus infection induces the upregulation of several inflammatory cytokines 
and chemokines such as IL-1β, IL-6, TNF-α, CCL-2 (MCP-1), CCL3 (MIP1-α), CCL3 
(RANTES) and CXCL10 (IP-10)[118]. Current literature has conflicting reports on the role 
of the cytokine and chemokine system during influenza infection. Some studies suggest 
that influenza virus infection triggers a robust inflammatory cytokine response or “cytokine 
storm” that is responsible for the pathogenesis of influenza while other studies identified a 
protective role. 
 
 
19 
  
2.4.4. Cells of innate immune system 
Natural killer cells 
Natural killer cells are a population of large granular lymphocytes with potent 
cytotoxic activity and robust production of inflammatory cytokines such as IFN-γ, tumor 
necrosis factor- alpha (TNF-α), and macrophage inflammatory protein-1 alpha (MIP-1α) 
[119-121]. While, NK cells are broadly reactive against a wide variety of pathogens 
including bacteria, virus, and intracellular parasites, their role during influenza is poorly 
defined. Two NK cells receptors, natural cytotoxic receptors (NCR) Nkp46 (NCR- in the 
mouse) and Nkp44, have been shown to recognize influenza virus HA on virus-infected 
target cells [122, 123]. Moreover, large numbers of NK cells accumulate in the lungs of 
infected host; and depletion or mutation of NK cell receptors resulted in increased 
morbidity and mortality [124, 125]. Furthermore, adoptive transfer of donor cells, even at 
<20% of the endogenous pulmonary NK cell content, resulted in restored protection [126]. 
Moreover, the differential activation of NK cells correlated with the pathogenicity of avian 
influenza viruses [127]. NK cells have also been shown to enhance both DCs [128] and the 
adaptive T-cell responses [129, 130] following influenza virus infection. Recently, it was 
found that type-I IFN, but not IL-12 or IL-18, as critical for NK cell expression of both 
IFN-γ and granzyme B in response to influenza infection [131].  
Alveolar macrophage cells 
 Alveolar macrophages (AM) are one of the primary phagocytic and predominant 
antigen presenting cells in the lungs. During homeostasis, AM are relatively quiescent and 
have a regulatory cell phenotypes [132]. These homeostatic AM are less phagocytic and 
produce relatively low amount of cytokines [132]. Interestingly, homeostatic AM have also 
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been shown to suppress the induction of innate and adaptive immunity [133-136]. 
However, these homeostatic AM can be activated during influenza infection and convert 
into highly phagocytic cells that produce robust amounts of inflammatory cytokines 
including IL-6 and TNF-α [137]. Influenza infected macrophages also produce chemokines 
such as RANTES, monocyte chemotactic protein-1 (MCP-1), and MIP-1α which further 
recruit more mononuclear cells to the lungs to aid in viral clearance [138]. Besides their 
contribution to viral clearance, especially in the case of seasonal influenza, AM have also 
been implicated in influenza virus pathogenesis [139, 140]. Nevertheless highly pathogenic 
IAV was found to induce significant recruitment of AM to the lungs [141, 142]. However, 
studies using depletion of AM suggest that these cells are critical in the early protection 
during influenza. Depletion of AM prior to, but not, 3 or 5 days following influenza 
infection resulted in uncontrolled viral replication and a significant increase in mortality 
[143]. Likewise, pigs depleted of AM prior to influenza infection exhibited increased 
respiratory stress, reduction in lung TNF-α levels and increased IL-10. AM depletion also 
reduced numbers of virus-specific CD8+ T-cells in the lungs and led to a diminished 
antibody response [144]. Taken together, these observations suggest that AM may have 
both protective as well as detrimental roles, due to excessive inflammatory cytokine 
production- during influenza virus infection; and a balanced AM response is essential in 
controlling the influenza virus infection. 
Dendritic cells 
 Dendritic cells are a unique population of cells that play a pivotal role in molding 
immune response against invading pathogens. DCs are one of the most potent antigen 
presenting cells (APC) and play a pivotal role in bridging the innate and adaptive immune 
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system following influenza virus infection. In the naïve homeostatic state, DCs are 
distributed throughout the respiratory tract including airway epithelium, lung parenchyma 
and the alveolar space of the lungs where they constantly survey for invading pathogens or 
foreign materials. While lung resident DCs constitute a heterogeneous population in terms 
of their surface phenotype and function, predominant DCs in the naïve lungs are airway 
and alveolar DCs characterized by expression of CD11c+MHCII+CD11bneg CD4negCD8neg, 
and interstitial DCs characterized as being CD11c+MHC II+CD11bhiCD4negCD8neg [145-
149]. Pulmonary insult or infection results in a significant influx of CD11c+MHCII+ DCs 
in to the lungs increasing in the number of alveolar DCs and interstitial DC, as well as 
recruitment of other subsets such as inflammatory monocyte derived DC (MoDC), pDC, 
and CD8α+ DCs [139, 150-152]. While most influenza viruses can infect DC and lead to 
viral protein synthesis, infection is generally abortive and does not produce progeny virus 
[153, 154]. However, some highly pathogenic H5N1 viruses have been described to 
replicate in human and mouse DCs and result in cytopathic effects [118, 155]. Following 
infection by or encounter with IAV, DCs initiate production of proinflammatory cytokines 
and chemokines that can include IL-6, IL-12, TNF-α, IL-8, IP-10, RANTES, MIP-1β, and 
most importantly, type-1 IFN (IFN-α and IFN-β) [156]. Type-I IFN possesses potent 
antiviral properties and is critical to the control of IAV infection. However, influenza virus 
possesses mechanism to subvert this critical antiviral response by virtue of its NS1 protein, 
and it will be discussed later in the current chapter. 
2.5. Pathogenesis of influenza  
Depending on the virus subtype and host, pathogenesis and outcome of influenza 
virus infection is variable. In a natural reservoir host, such as wild waterfowls, influenza 
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virus replication is limited to the gastro-intestinal tract and does not cause clinical disease 
[157]. In general, influenza virus infection is also mild and non-fatal in other avian species 
such as domestic poultry, turkey, quail and pheasants. However, some H5 and H7 strains 
are highly pathogenic in birds and responsible for large scale outbreaks in recent years 
[158]. In mammals, including humans and equines, influenza virus causes a respiratory 
disease that could range from mild to highly fatal in severity. Uncomplicated cases of 
seasonal influenza in human are characterized by symptoms such as fever, headache, sore 
throat, malaise, anorexia and coughing. The virus primarily infects and replicates in ciliated 
columnar epithelial cells of the upper respiratory tract and subsequently infects cells of the 
lower respiratory tract. Macroscopic pathogenesis of influenza involves physical damage 
to respiratory epithelium, increased cellular infiltration and respiratory edema. The 
molecular basis of the pathogenesis is mainly due to shut down of host cell protein 
synthesis, apoptosis, inhibition of cellular anti-viral factors, and modulation of cellular 
signaling molecules that results in altered cytokine/ chemokine response. Modulation of 
respiratory cytokine and chemokine milieu by influenza virus also results in altered 
recruitment of the effector cells of the respiratory innate and adaptive immune systems. 
Influenza virus NS1 has a predominant role in the pathogenesis of the influenza virus and 
will be discussed below. Secondary bacterial infection also plays a major role in the 
pathogenesis and mortality associated with influenza and its role during influenza will be 
reviewed later in the current chapter. 
2.6. Role of NS1 in pathogenesis and immunity to influenza 
Although the NS1 protein is not a structural component of the virion, it is expressed 
at very high levels in the infected host cells and performs various functions critical for 
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pathogenicity and replication of IAV.  NS1 has been shown to inhibit critical steps of the 
host innate as well as adaptive immune responses. NS1 has also been implicated as a critical 
factor in several other viral functions including control of viral replication [159], 
facilitation of viral mRNA translation [160], inhibition of host mRNA processing [161-
163], and regulation of apoptosis [164, 165]. 
2.6.1. Antagonism of cellular antiviral mechanism  
One of the well-studied functions of the NS1 protein of the influenza viruses is to 
inhibit host type-I IFN mediated antiviral defense. By using IAV with a truncated form of 
NS1 or complete deletion of NS1 (delNS1) it was shown that NS1 is critical in 
counteracting the host IFN response [166-168]. Whereas, delNS1 viruses replicated 
efficiently in IFN-deficient systems such as vero cells, these viruses were highly attenuated 
in an IFN-competent system [169]. The attenuated phenotype of these viruses might be due 
to potent induction of the IFN-α/β in IFN-competent system [167]. Several groups have 
investigated the mechanism of NS1 mediated inhibition of Type-I IFN, and it is now 
evident that, depending on the strain, NS1 anti-IFN activity could either be at pre-
transcriptional or post-transcriptional level [170-172]. IFN antagonistic activity of NS1 
protein of PR8 relies on blocking the dsRNA-and virus- mediated activation of key 
regulators of IFN-β mRNA transcription such as interferon regulatory factor-3 (IRF-3), 
NFκB and c-jun/ATF-2 that are essential for IFN-β mRNA synthesis [173-175]. Post-
transcriptional inhibition of IFN-β by NS1 is mediated by its interaction with CPSF30 and 
PABPII. Studies using IAV Udorn/72 (Ud) found that the C-terminal effector domain of 
Ud-NS1 binds to two zinc finger domains of CPSF30 [176, 177] and interacts with PABPII 
[57]  resulting in inhibition of polyadenylation and nuclear export  of cellular mRNAs. 
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OAS and the PKR are the two major cytoplasmic anti-viral proteins. Besides their key roles 
in regulation of viral transcription and translation, both of these proteins have critical roles 
in other innate defense mechanisms of the host such as IFN-β induction and apoptosis [178, 
179]. Influenza virus NS1 has been shown to directly inhibit OAS [60] as well as PKR 
[180]. A key event for the activation of OAS is binding of dsRNA, therefore RNA binding 
activity of NS1 could lead to inhibition of OAS [181]. Since RNaseL of the OAS pathway 
also participates in IFN-β induction [179], inhibition of OAS could also lead to suppression 
of IFN-β [174, 182]. Binding of dsRNA releases the auto-inhibition of PKR and leads to 
activation. Thus the dsRNA binding activity of NS1 was thought to result in competitive 
inhibition of PKR [183, 184]. However, Li et al., observed that an NS1 protein defective 
in dsRNA binding efficiently blocked the activation of PKR [185]. Moreover, NS1 was 
also reported to interact with PKR through a dsRNA–independent mechanism that involved 
critical role of residues 123-127 [180, 185]. Domain mapping studies suggest that NS1 
binds to a linker region of PKR that prevents a conformational change otherwise required 
to release autoinhibition [185]. Additionally, to counteract the effect of PKR, influenza 
virus activates a latent chaperon related protein p58IPK that interferes with dimerization 
and activation domain of PKR [186, 187], and has been shown to prevent apoptosis [188]. 
Activation of PKR leads to phosphorylation of cellular eIF2-α that results in reduction of 
viral as well as cellular protein synthesis [178]. Inhibition of eIF2α is also critical in 
regulation of ER stress-induced transcription factor CHOP-10 and induction of CHOP-10 
is a key factor in deciding the fate of infected cell. While at early time points it helps to 
restore the ER homeostasis, prolonged induction of CHOP-10 leads to apoptosis. 
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2.6.2. NS1 and RNA interference (RNAi) pathway 
 Although the role of mammalian RNAi pathway in innate anti-viral defense is not 
well established, NS1 has been suggested to antagonize putative RNAi-mediated innate 
anti-viral mechanisms [189]. Whereas NS1 inhibited the host RNAi pathway in drosophila 
and plant cell systems [190, 191], it has not been observed in the mammalian cells [192]. 
2.6.3. NS1 and apoptosis  
 Although the biological consequence of apoptosis during influenza virus infection 
is yet to be defined, apoptosis is widely accepted as a cellular antiviral mechanism to limit 
viral replication. While inhibition of apoptosis early during infection could promote events 
such as viral replication, later during infection apoptosis may help in the efficient release 
of progeny virus [193]. Influenza virus has been shown to possess anti-apoptotic activities 
[165, 194-196]. Conversely, certain viral protein such as PB1-F2 and NA have been shown 
to have pro-apoptotic activities [43]. The role of NS1 in apoptosis is controversial, and it 
has been shown to have both pro-apoptotic [164, 197] as well as anti-apoptotic activities 
[165, 196]. In MDCK cells, Zhirnov et al., observed that, as compared to the wild type PR8 
virus, isogenic delNS1 virus induced higher level of apoptosis [165]. Although such 
conflicting results may be due to differences in the experimental setup, there is an emerging 
hypothesis that NS1 temporally regulates both early suppression and late induction of 
apoptosis [51].  Activation of PKR during influenza virus infection has also been reported 
to play a role in apoptosis [198]. Thus, direct binding and inhibition of PKR by NS1 could 
also suppress apoptosis [51]. Likewise, suppression of the pro-apoptotic activity of 
OAS/RNaseL [60] or the JNK/AP-1 stress pathway [173] could also contribute to anti-
apoptotic activity of NS1. Influenza virus activates the PI3K/Akt pathway by the binding 
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of NS1 to the p85 subunit of PI3K [199-201] and by viral RNA via RIG-I [202]. Activation 
of the PI3/Akt pathway by NS1 limits the early induction of apoptosis [195, 200, 203].  
2.6.4. NS1 and dendritic cell functions 
 Influenza virus NS1, in addition to its effect on innate antiviral defenses, also 
interferes with critical components of the adaptive immune response. DC are the critical 
sentinel cells of the adaptive immune system. Upon an encounter with foreign antigens, 
DCs undergo maturation, release proinflammatory cytokines/chemokines and migrate to 
lymph nodes where they present pathogen specific antigens to cytotoxic and helper T-cells 
[193]. Presentation of antigens by dendritic cells activates cytotoxic T-cells that directly 
kill the infected cells to eliminate the pathogen, whilst helper T-cells produce cytokines 
such as IFN-γ and TNF-β that augment the cytotoxic activity of T-cells. NS1 protein of 
influenza virus has been shown to reduce systemic and respiratory cytokines and prevent 
TNF-α mediated depletion of bone marrow lymphocytes [204]. Influenza virus NS1 has 
also been shown to interfere with the activation and maturation of DCs. Using a PR8 virus 
mutant lacking NS1 and Newcastle disease viruses engineered to express NS1, Fernandez-
Sesma et al., found that NS1 inhibited expression of several genes crucial for the 
maturation, migration and T-cell stimulatory activity of DCs [205]. Dendritic cells infected 
with wild type PR8 virus failed to mature and did not induce secretion of IFN-γ from helper 
T-cells. Additionally, NS1 affected only a specific set of genes that mechanistically appear 
independent of IFN-β production. Important genes affected by NS1 included MIP-1β, IL-
12p35, IL-23p19, RANTES, IL-8, IFN-α/β, and CCR7 [205]. Monocytes are important 
progenitor cells of DCs. Infection of equine peripheral blood monocytes with influenza 
virus inhibited the differentiation of monocytes into DCs in response to GM-CSF and IL-
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4 [153]. Despite a non-productive infection, infected monocytes displayed a morphology, 
functional characteristics and cytokine profiles suggestive of arrested differentiation [153].  
Reactivation of memory T-cells by bone marrow-derived DCs has been shown to be critical 
in protection against influenza [206] therefore, prevention of DC maturation by NS1 has 
important implications in viral clearance by the host. 
2.7. Influenza and bacterial synergy 
 Although infection with some highly virulent influenza viruses alone can kill the 
host, influenza-associated death may also be due to exacerbation of physiologic stress from 
chronic health conditions or secondary bacterial infections. Among these, secondary 
bacterial infections appear to be the most common cause of death due to influenza, 
especially during pandemics [207]. Although Streptococcus pneumoniae (S. pneumoniae) 
has been the most common bacteria, other bacteria such as S. aureus   and H. influenzae 
have also been linked to influenza-associated  secondary bacterial pneumonia  [207] [208]. 
The earliest associations between influenza and bacterial pathogens date back to the 17th 
century when French physician Laennec observed increased cases of pneumonia following 
an epidemic of influenza (“la grippe”) in 1803 [209]. In 1935 Andrewes et al. were first to 
confirm secondary bacterial pneumonia following influenza infection where virus was 
recovered from a patient who was febrile and then developed pneumococcal pneumonia 
seven days into his convalescence and died [210]. The 20th century has seen at least three 
well-defined influenza pandemics- “Spanish flu” (1918-19, H1N1), Asian flu (1957, 
H2N2), and Hong Kong flu (1968-69, H3N2) resulting in 675,000 [211], 86,000 [212] and 
56,300 [213] death, respectively, in the United States. The pandemic of 1918, which killed 
about 40-50 million people worldwide [214], mostly due to secondary bacterial pneumonia 
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[215-219], brought the focus on synergy between  influenza and bacterial pneumonia. In 
the following years, several epidemiological and laboratory studies were conducted that 
supported secondary bacterial pneumonia as the major cause of death during influenza 
infections. In the investigation of an epidemic in Boston during the winter of 1943-44, 
Finland et al., [220] observed high titers of antibodies against IAV (PR8) from the cases of 
bacterial pneumonia during and immediately following the epidemic and concomitant with 
history of clinical influenza. They also isolated influenza virus from the lungs of three fatal 
cases and concluded that the severity of the pneumonia was due to preceding influenza 
infection [220]. In a study of an influenza epidemic in the Baltimore area during March-
April of 1947, using virus isolation and serology, Maxwell et al. reported that 47% (17/36) 
of cases of lobar pneumonia in humans were due to simultaneous infection with influenza 
and pneumococcus [221]. Similar findings were reported by Tyrrell in an influenza 
outbreak in Sheffield in 1949 [222]. In order to determine what killed the patients during 
the 1918-1919 pandemic influenza, Morens et al., re-examined hematoxylin and eosin-
stained sections recut from the lung blocks obtained from 58 victims of the 1918 outbreak 
available in the National Tissue Repository of the Armed Forces Institute of Pathology 
[223]. The authors also reviewed 1539 pathology and bacteriology research records that 
included 8398 individual autopsies from the 1918-1919 pandemic. From the 
histopathological, epidemiological and microbiological data they suggested that a 
synergistic association between influenza and bacterial pneumonia was responsible for the 
unprecedented mortality seen during the 1918-1919 pandemic [224, 225]. Based on gross 
pathology and bacterial isolation from blood only, 96% of 8000 cases reviewed showed 
secondary bacterial infection [225]. Even with the widespread availability of antibiotics, 
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more than two-thirds of fatal cases during the 1957 pandemic were associated with 
bacterial pneumonia [207]. Recent epidemiological studies also suggest that influenza 
infection predisposes the host to secondary bacterial infection. In a prospective study of 
lower respiratory tract infection of 154 children, Michelow et al., observed that 23% of 
children with identified pathogens showed influenza-associated secondary bacterial 
pneumonia resulting in heightened lung inflammation and disease severity [226]. 
Similarly, in an epidemiological study using binomial regression, Grabowska et al., 
reported a yearly increase of 12-20% in invasive pneumococcal disease (IPD) per influenza 
season, confirming a strong association between influenza and IPD [208]. The Center for 
Disease Control (CDC) evaluated the lung tissue from 77 fatal cases from the 2009 
pandemic influenza (H1N1) and observed that concurrent infection of bacterial pathogens 
was evident in approximately one-third of the cases, approximately 50% of those cases 
were due to S. pneumoniae [227].  
 Animal models for secondary bacterial infection following influenza were 
attempted soon after the pandemic of 1918 [228]. In 1945, Mercedes and Torregrosa 
developed a mouse model for secondary bacterial pneumonia [229]. Using the mouse-
adapted Influenza virus A / Puerto Rico/8/34 (PR8) and different strains of H. Influenzae, 
S. Pneumoniae and S. aureus, they observed that preceding influenza infection resulted in 
increased severity of bacterial pneumonia. Recently, McCullers et al., also developed a 
similar mouse model to study the synergistic relationship between IAV and S. Pneumoniae. 
They observed that influenza infection preceding the pneumococcal challenge increased 
the severity of pneumonia and resulted in 100% mortality in mice. On the other hand, 
pneumococcal infection preceding influenza infection resulted in protection from influenza 
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and improved survival [230]. Although the relationship between influenza and 
pneumococcus has been known for centuries [209], there are discrepancies that need to be 
resolved. While laboratory animal experiments support synergy between pneumococcus 
and influenza [231, 232] epidemiological data shows either limited association at best [233, 
234] or no association [235].  Shreshta et al., developed a computer model that integrates 
weekly incidence reports and a mechanistic transmission model within a likelihood-based 
inference framework to define the nature, strength and temporal interaction between 
influenza and pneumococcal pneumonia.  Using their model, they analyzed weekly reports 
of influenza and pneumococcal pneumonia from Illinois from 1989-2009 and observed that 
influenza infection increased the susceptibility for pneumococcal pneumonia by 
approximately 100 fold for a week following the initial influenza infection [236]. 
Mechanism of Synergy 
Bacterial pneumonia during influenza could either be due to combined 
viral/bacterial pneumonia or a secondary complication following influenza. Combined 
viral/bacterial pneumonia has about a 10% mortality rate and is at least three times more 
common than primary viral pneumonia [237]. Furthermore, differentiation of primary viral 
or bacterial pneumonia is clinically challenging.  Chest radiographs of patients with 
advanced cases of viral pneumonia usually show bilateral interstitial infiltrate similar to 
bacterial pneumonia [238]. Inflammatory markers also fail to distinguish between primary 
viral and bacterial pneumonia. Secondary bacterial pneumonia with a mortality rate of 
about 7%, on the other hand, is easily recognizable as it develops during the recovery phase 
of influenza [239, 240]. Pathogenesis of influenza-associated bacterial pneumonia is 
multifactorial and differs between concurrent bacterial infection and infection following 
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influenza. It is important to note that concurrent viral/bacterial infection is relatively more 
complex than post-influenza pneumonia. In combined viral/bacterial infection, both the 
bacteria and the virus elicit a host defense response that could affect growth of both or the 
other. On the other hand, pneumonia following influenza involves virus-induced changes 
to the host and host response to bacteria [241, 242].   
Physical changes in respiratory epithelium  
Increased bacterial adherence to the damaged respiratory epithelium due to 
influenza virus replication is the earliest explanation for increased susceptibility to bacterial 
superinfection [243, 244]. Bacteriology and histopathology of lungs from the fatal cases of 
hospital-acquired S. aureus pneumonia during 1957-58 influenza pandemic, showed 
increased bacterial adherence in the areas of the bronchial tree where influenza virus 
replication had denuded the epithelial layer [245]. Influenza virus infection can expose 
basal membrane components such as fibrin that facilitate attachment of bacteria. In mice 
infected with PR8 virus, and subsequently with S. pneumoniae, desquamation of tracheal 
epithelium caused exposure of the basal cell layer and exposed basal membrane component 
that favored the adherence of S. pneumoniae [246]. Additionally, influenza virus NA that 
cleaves terminal sialic acid from cell surface glycoproteins could generate alternate 
receptors, or virus-induced inflammation could activate some inactive cellular receptors 
for bacteria [209, 230]. In a tracheal organ perfusion system, exogenous administration of 
NA results in an increased number of receptors and adherence of S. pneumoniae [247]. 
Using a mouse model, McCullers and Bartmess found that influenza virus NA facilitates 
bacterial adherence by stripping sialic acid from the lung, exposing receptors for 
pneumococcus. Administration of selective NA inhibitor (Oseltamivir) improved survival 
 
32 
  
and morbidity from influenza independent of viral replication [248]. Pairs of otherwise 
isogenic influenza viruses generated by reverse genetics to express different N2 subtype 
NAs showed a differential attachment of S. pneumoniae and development of pneumonia 
proportional to the activity of expressed NA [249]. Besides NA, PB1-F2 of influenza has 
also been implicated in the susceptibility to secondary bacterial pneumonia. Mice infected 
with influenza viruses lacking PB1-F2 showed decreased susceptibility to secondary 
infection [207]. Mice infected with a viral strain engineered to express PB1-F2 protein of 
1918 pandemic influenza were more susceptible to pneumococcal pneumonia [250]. A 
possible mechanism involves excessive lung damage and enhanced inflammatory 
response; however, the exact underlying mechanism is unknown [207]. Upregulation of 
cryptic cellular receptors might also contribute to increased bacterial susceptibility. 
Influenza virus infection induces inflammatory cytokines that result in upregulated 
expression of platelet activating factor receptor (PAFR) that can be used by pneumococci 
for attachment [251]. The role of PAFR in bacterial superinfection, however, is 
controversial. Influenza infected PAFR deficient mice infected with S. pneumoniae showed 
significantly reduced bacterial outgrowth in the lungs, reduced dissemination of the 
infection and prolonged survival [252]. However, antibody-mediated neutralization of 
PAFR had no effect on secondary bacterial infection in influenza-infected mice [230]. 
Additionally, reduced clearance of bacteria from the influenza-infected lungs could also 
predispose the host to increased bacterial burden. Influenza infection can result in 
decreased function of surfactant protein and increased mucinous secretions that together 
with fibrin and edema fluid and cellular infiltrate result in a dead space and ideal culture 
conditions for bacteria [244, 253]. Impairment of the mucociliary escalator mechanism has 
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also been observed during influenza [254, 255]. Substantial reduction in mucociliary 
velocity was observed in influenza-infected tracheas as compared to the non-infected 
tracheas [256]. Therefore, it appears that influenza infection results in decreased clearance 
of bacteria leading to increased bacterial burden in the lungs.  
Defective cellular innate defense 
 Although, defects in recruitment or activation of immune effector cells, such as 
neutrophils, have also been implicated in enhanced bacterial superinfection during 
influenza infection, their role is controversial. While most studies observed a reduced early 
recruitment of neutrophils after subsequent bacterial challenge of influenza-infected mice, 
some studies found that neutrophil recruitment 24 hrs post bacterial challenge is either 
uninhibited or sometimes increased [242, 257-259]. Irrespective of levels of neutrophil 
recruitment in the lungs, defects in the bactericidal functions of these cells such as 
phagocytosis, respiratory burst, myeloperoxidase production and lysozyme production 
have been detected [257, 260, 261]. Macrophage cells are strategic resident immune 
effector cells in the lungs and act as immune sentinels for bacterial infections. Influenza 
and other respiratory viruses have been shown to inhibit chemotaxis, phagocytosis and 
microbicidal function of macrophage and monocytes. In the influenza infected individuals, 
monocyte chemotaxis was suppressed 40%-72% during acute infection and reverted back 
to normal by three weeks after recovery. Increased susceptibility to bacterial superinfection 
in influenza patients can also be due to the virus-mediated suppression of monocyte 
function [262].   In a mouse model, Kleinerman et al., found that, compared to the non-
infected mice, influenza-infected mice showed 57% and 65% depression of total leukocyte 
and macrophage accumulation, respectively. On the other hand, bacterial pneumonia did 
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not suppress the macrophage response, suggesting that macrophage inhibition was 
specifically due to influenza virus infection [263].  In dual infected mice, bacteria were 
primarily bound to resident AM cells. Furthermore, depletion of alveolar macrophage cells 
with liposomal Clodronate™ resulted in bacterial outgrowth in lung tissue as well as in 
alveoli [264]. Defects in NK cell function has also been proposed to contribute to secondary 
bacterial infections. In the mouse model, preceding influenza infection resulted in impaired 
NK cell response to subsequent S. aureus infection. Adoptive transfer of naïve NK cells 
restored the impaired host antibacterial response. This NK cell dependent impairment of 
host antibacterial defense was due to reduced TNF-α production by NK cells that resulted 
in depression of macrophage activation [265]. 
Dysregulated cytokine response 
 A fine balance of pro-inflammatory and anti-inflammatory cytokines is central in 
determining the outcome of the immune response. A dysregulation of the cytokine and 
chemokine balance during influenza has been observed and suggested to promote tissue 
injury, as well as impair bacterial clearance. Increased production of pro-inflammatory 
cytokines such as TNF-α, IL-6, IL-1β and chemokines, commonly referred to as a cytokine 
storm, has been reported to contribute to the pathology of influenza infection of animals as 
well as humans [257, 266]. Conversely, Shahngian et al., observed that influenza infection 
resulted in decreased production of neutrophil activating chemokines such as MIP-2 and 
keratinocyte-derived chemokine [KC] [259]. Imbalance in the release of anti- and pro-
inflammatory cytokines could also suppress the effector response of innate immune cells. 
Besides inflammatory cytokines, influenza virus also stimulates anti-inflammatory 
cytokines such as IL-10 [266]. IL-10 limits both systemic as well as respiratory 
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inflammatory cytokine response of the host [267]. Additionally, enhanced release of IL-10 
also results in suppression of leukocyte activity and impaired antibacterial response in the 
lungs [268]. In a mouse model of post-influenza secondary pneumonia, Van der Slujis et 
al., [242] observed that higher IL-10 levels, at least in part, were associated with increased 
susceptibility to secondary infection with S. pneumoniae. Mice recovered from influenza 
infection showed 50-fold higher expression of IL-10 in their lungs as compared to the lungs 
of control mice. Furthermore, treatment with an IL-10 antibody before bacterial challenge 
reduced the bacterial outgrowth and lethality of secondary pneumonia as compared to the 
IgG1 control antibody treated mice [242]. However, studies with IL-10 knockout mice did 
not show any improved outcome after dual infection [269]. Transforming growth factor-β 
(TGF-β) is another important anti-inflammatory cytokine that has been implicated in 
influenza-associated susceptibility to secondary bacterial infections. TGF-β is synthesized 
as an inactive factor that needs to be cleaved to generate a biologically active form of TGF-
β. Latent TGF-β remains linked with latency-associated peptide (LAP) attached non-
covalently to the amino terminus of the immature TGF-β protein. Release of LAP from 
TGF-β is essential for its binding to cellular receptors [270]. Influenza virus neuraminidase 
is capable of processing the latent TGF-β to its active form in vitro resulting in increased 
serum TGF- β activity as early as day one post-influenza infection [271]. Although 
interferons including IFN-γ and type-I IFN (IFN-α and -β) are primarily believed to 
participate in antiviral immunity, recent studies also support their role in suppressing 
secondary bacterial infections. Sun and Metzger [231] reported that during influenza 
infection, pulmonary T-cell produced IFN-γ inhibits bacterial phagocytosis by alveolar 
macrophage cells and leads to increased susceptibility to secondary pneumococcal 
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infection. Whereas exogenous administration of IFN-γ mimics the effect of influenza 
infection and increases secondary bacterial susceptibility, neutralization of pulmonary 
IFN-γ restores antibacterial immunity. Also, mice deficient in either IFN-γ or IFN-γ 
receptor showed significant bacterial clearance as compared to wild type mice [264]. Type-
I IFN such as IFN-α or IFN-β are soluble cytokines that act as the first line of defense 
against viral infections and establishment of antiviral state and activation of various 
immune cells [272] [273]. Influenza virus NS1 is a potent antagonist of IFN-α/β antiviral 
responses [193]. Studies using influenza viruses engineered to express either truncated 
forms of NS1 or lacking NS1 confirmed the role of this protein in counteracting host IFN 
response [169, 274, 275]. Influenza viruses lacking NS1 (DelNS1) induce large amounts 
of type-I IFN and are, therefore, highly attenuated in IFN-α/β competent system [193] and 
display pathogenicity only in mice lacking antiviral signaling components such as STAT-
1 [276]. Influenza virus has also been shown to block IFN mediated anti-viral signaling. 
Expression of H5N1 NS1 in HeLa cells suppresses IFN signaling in part due to NS1-
mediated inhibition of expression of the IFN receptor subunit [273]. Infection of ex-vivo 
human non-tumor lung tissue with H5N1 and H1N1 viruses resulted in downregulation of 
ifanr1 expression. Furthermore, infection of human monocyte-derived macrophages with 
H5N1 and H1N1 viruses suppressed ifnar1 and ifnar2 expression [273]. Interestingly, IFN 
receptor null mice (ifnr-/-) showed resistance to secondary infection with S. pneumoniae 
when compared to wild type control mice [259]. Mice deficient in IFN receptor produced 
significantly higher amounts of CXC chemokine resulting in greater recruitment of 
neutrophils in the lungs [259]. Some studies suggest that the type-I interferon-mediated 
suppression of TLR signaling through TRIF participates in regulating pro-inflammatory 
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cytokines and chemokines [277]. However, the mechanism underlying the IFN mediated 
suppression of chemokines is still poorly defined.  
2.8. IL-23/IL-17 axis of innate immune response 
IL-23 is a member of the IL-12 family of heterodimeric cytokines [278]. Functional 
IL-23 is composed of a unique subunit-IL-23p19 and p40 subunit which is shared with IL-
12. Although IL-23p19 is expressed by a variety of tissues, it lacks any functional activity 
by itself. Indeed, only activated macrophages and DCs secrete the biologically active IL-
23 heterodimer [279]. Since IL-23 also shares receptor IL12Rb1 with IL-12, it was 
expected to have similar roles as IL-12 in promoting T helper 1 (Th1) type responses. 
However, it has become evident now that IL-23 has different roles in regulating the 
immune response. Importantly, IL-23 is a key factor in the development and maintenance 
of a subpopulation of CD4+T cells called Th17 cells [280]. Based on the cytokine profiles 
and functional properties, Mosmann et al., [281] proposed two classes of helper T (Th) 
cells as Th1 and Th2 cells which participate in cell mediated immunity and humoral 
immune response, respectively. After about two decades, an IL-23 dependent subset of 
CD4+T cells, distinct from Th1 and Th2 cells, characterized by IL-17 secretion was 
identified [282]. These Th17 cells do not express the  T-bet or GATA3 lineage-specific 
transcription factors of Th1 and Th2 cells, respectively [283, 284]. 
Initial studies found the IL-23/IL17 immune axis  to be a major contributing factor 
in the development of autoimmune diseases including experimental autoimmune 
encephalomyelitis (EAE) [285], collagen–induced arthritis (CIA) and inflammatory bowel 
disease (IBD) [reviewed by 286]. By studying the onset of EAE in IL-12p35, IL23p19 and 
IL-12/23p40 knockout (KO) mice, Cua et al., reported that IL-12/23p40 KO mice were 
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resistant but IL-12p35 KO mice were susceptible to EAE. They further observed that IL-
23p19 deficient mice were resistant to disease, indicating that IL-23 was important in the 
development of EAE [287]. Likewise, it was found that IL-12p35 deficient mice were more 
susceptible to CIA following immunization with type II collagen in complete Freund’s 
adjuvant, whereas IL-23p19 or IL-12/23p40- deficient mice did not develop the disease 
[288]. Recent evidence, however, also suggests a protective role of the IL-23/IL-17 axis in 
the innate immune responses. Exposure of macrophages and DCs to lipopolysaccharides 
(LPS) and other microbial products leads to the secretion of IL-23 from these cells [279, 
289, 290], that induces a rapid release of IL-17 cytokines from Th17 cells [280, 291].  The 
IL-17 cytokine family consist of six members (IL-17 A, B, C, D and F), however; only IL-
17A and IL-17F have been studied well and will be referred as IL-17 hereafter. Endothelial 
cells and macrophage cells express IL-17 receptor and apparently are the main targets of 
IL-17. IL-17 signaling in these cells results in induction of several pro-inflammatory 
cytokines, including IL-6, IL-1β, IL-8 and TNF-α, which mediate host defense; as well as 
several neutrophil chemoattractants such as CXCL-1, CXCL2, and CXCL5 that mediates 
neutrophil recruitment to the infection site. Thus, the IL-23/IL17 immune axis might be an 
important driving force in early immune responses against invading pathogens. IL-17 also 
induces cytokines for targeting other immune cells to the mucosal surfaces. These include 
CXCL9, CXCL10 and CXCL20 that possess chemotactic activity for lymphocytes and 
DCs, and CCL2 and CCL7 that recruit monocytes. Additionally, IL-17 also induces some 
antimicrobial peptides which can directly kill the pathogens [2]. Moreover, some of the 
chemokines such as CCL20 also exhibit antimicrobial activity [292]. 
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2.9. IL-23/IL-17 axis and immunity against pathogens  
A protective role of the IL-23/IL-17 immune axis has been reported against many 
bacterial and fungal pathogens [reviewed by 2]. IL-17 has been found to be critical for 
recruitment of phagocytes that leads to the clearance of S. pneumoniae from the mucosal 
surface of the nasopharynx [293]. Happel et al., found that IL23p19, IL-17 receptor (IL-
17R) and IL12p35 deficient mice were more susceptible to infection following 
intrapulmonary inoculation with Klebsiella pneumoniae. They also observed that IL23p19 
deficient mice had significantly lower IL-17A and IL-17F production in lungs, and despite 
the normal IFN-γ levels in the lungs, these mice showed significant mortality from a 
sublethal dose of bacteria (103 CFU). Notably, administration of recombinant IL-17 
restored the protection against bacterial infection [294]. In a mouse model of streptococcus 
lung infection, inhibition of the IL-23/IL-17 axis by morphine resulted in diminished 
release of antimicrobial proteins S100A8/A9, reduced neutrophil recruitment and more 
severe streptococcal infection in the lungs [295]. Markel et al., found that exogenous 
administration of IL-17 or IL-23 had improved survival rates in pulmonary infection with 
live vaccine strain (LVS) of Francisella tularensis, albeit to a limited extent. On the other 
hand, antibody-mediated neutralization of IL-17 resulted in significantly higher mortality 
(66.6%) as compared to the control mice infected with sublethal LVS [296].  
Although the role of the IL-23/IL17 axis against bacterial pathogens has received 
much attention, its role in viral infection is less explored, and there are conflicting findings. 
The role of IL-12, IL-23 and IL-17 on viral host defense in poxvirus infection was 
evaluated using vaccinia virus (VV) genetically engineered to express IL-12 (VV-IL-12), 
IL-23 (VV-IL-23) or IL-17 (VV-IL-17) [297]. It was observed that VV-IL-23 and VV-IL-
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17 were less virulent in BALB/c mice as compared with VV-IL-12 virus. Additionally, in 
IFN-γ deficient mice infected with VV-IL-23 neutralization of IL-17 using anti-IL-17mAb 
resulted in a significant increase in viral titers [297]. These findings suggested a protective 
role of IL-23/IL-17 axis against VV. On the contrary, Patera et al., reported that VV-IL-17 
was more virulent than the parental virus in mice, possibly due to altered generation of IgG 
isotype antibodies [298]. Similarly, contrasting findings on the role of the IL-23/IL-17 axis 
during influenza virus infection have also been reported. In mice infected with 100 PFU 
IAV (PR8), IL-17A and IL-17F was induced as early as two days post-infection [299]. 
When mice deficient in IL-17R were challenged with PR8 virus, they showed less weight 
loss and better survival rates than the wild type mice. Also, inflammation was less severe 
in the IL-17 deficient mice as compared with wild type mice, possibly due to reduced 
neutrophil infiltration and lower levels of IL-17 induced proinflammatory cytokines in IL-
17R deficient mice [299]. In contrast, when c57BL/6 mice challenged with 100 PFU of 
influenza virus (PR8) for six days were subsequently challenged with 108 CFU of S. 
aureus, clearance of both the bacteria and virus were attenuated. In addition, IL-17R and 
IL-22 deficient mice had impaired bacterial clearance compared to the wild type mice. 
Furthermore, exogenous supplementation of IL-23 via an adenovirus expressing IL-23 
resulted in decreased lung inflammation, increased IL-17A and Th17 chemokines, and 
increased clearance of bacteria and virus. Therefore, it appears that IL-23 overexpression 
helps to restore the bacterial immunity and prevent increased susceptibility to secondary 
bacterial infection [300].  These observations imply that the IL-23/IL-17 axis might have 
a detrimental as well as protective effect during influenza virus infection. Therefore, to 
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resolve this question, the relationship between the IL-23/IL-17 axis, influenza virus and 
secondary bacterial infection needs further investigation.   
2.10. Regulation of IL-23 expression 
 Although IL-23 has protective roles during the early innate immune response, its 
chronic activation has been implicated in autoimmunity. Thus, a fine regulation of its 
synthesis and secretion is necessary. IL-23 is a heterodimeric cytokine and formation of 
biologically active IL-23 (p19/p40 heterodimer) requires synthesis of both the subunits 
within the same cell. Therefore, regulation of IL-23 specific p19 subunit is critical in 
determining secretion of biologically active IL-23. Transcriptional regulation of p40 
(shared subunit) has been studied well, and it is now known that its expression is controlled 
by various transcriptional factors such as NF-κB, C/EBP, ets-2, PU.1 and AP-1 [301-305]. 
However, owing to the recent discovery of p19, very little is known about the 
transcriptional regulation of IL-23, or more specifically p19.  Transcription factor NF-κB 
was found to be critical for the expression of IL23p19 in dendritic cells [306] and 
macrophages [307]. Liu et al. demonstrated that the ERK pathway was essential for IL-
23p19 gene expression. They also identified an Ap-1 element in the IL-23p19 promoter 
and established that AP-1 was required for the IL-23p19 expression [308]. More recently, 
Goodall et al. investigated the role of the endoplasmic reticulum (ER) stress pathway in 
the expression of IL-23 in human dendritic cells. They found that ER stress-induced 
transcription factor CHOP-10 was crucial for the IL-23 expression [309]. Their study 
suggests that ER stress-induced by invading microorganisms could significantly affect the 
IL-23-IL-17 mediated host innate immune response. 
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2.11. Influenza virus and IL-23/IL-17 axis 
 The effect of influenza virus on IL-23 expression has not been investigated. In 
human primary macrophages, Pirhonen et al., showed that, unlike Sendai virus, influenza 
virus did not induce IL-23 [310]. Recently, Kudva et al., investigated inhibition of IL-23 
by influenza virus. They found that when IFN-α receptor knockout (IFN-αR-/-) mice were 
challenged by influenza virus and subsequently with S. aureus, preceding influenza virus 
infection did not inhibit IL-23 or IL-22 production in IFN-αR deficient mice. Therefore, 
they concluded that IAV induced type-IFN (IFN-β) is responsible for inhibition of the IL-
23 in lungs [300]. However, Fernandez-Sesma et al., observed that, as compared to the 
dendritic cells infected with wild type virus, an NS1 deletion mutant influenza virus 
(PR/8/34 DeltaNS1) induced significantly higher expression of both IFN-β, as well as IL-
23p19 [274]. Therefore, a different mechanism must exist for influenza virus mediated 
inhibition of IL-23. Considering the role of ER stress-induced transcription factor CHOP-
10 on IL-23p19 expression, one such mechanism of influenza virus mediated suppression 
of IL-23-IL-17 axis could be inhibition of CHOP-10. 
2.12. Influenza virus and ER stress response 
 Protein overload in the ER activates a signaling cascade collectively called the 
unfolded protein response (UPR), which tries to resolve increased protein load. IRE1, 
PERK and ATF6 are the sensors of ER stress and initiate downstream signaling events to 
reduce the protein overload and increase cell survival. Activated IRE1 has 
endoribonuclease activity, and it performs alternative splicing of XBP-1 mRNA with a 
frame-shift leading to a premature stop codon and production of the active XBP-1 
transcription factor [311, 312]. Active XBP-1 then translocates to the nucleus and activates 
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transcription of ER chaperon genes involved in ER protein folding. ATF6 is an ER resident 
transmembrane protein which in the event of ER stress is cleaved by serine proteases in 
Golgi apparatus and translocates to the nucleus where it activates transcription of UPR 
target genes. PERK is an eIF2α kinase which helps in reducing ER overload by attenuating 
protein synthesis through phosphorylation of eIF2α [313]. Phosphorylation of eIF2α, 
however, results in preferential translation of ATF4 that activates downstream targets, 
including CHOP-10. There are two possible outcomes of the UPR pathway activation -
either the cell resolves the protein overload issues and survives or if it fails to resolve the 
protein overload apoptosis ensues. Levels of CHOP-10 have a crucial role in determining 
the fate of the cells as its long-term induction results in apoptosis such as in the case of 
prolonged ER stress in the cell.  
 The effect of influenza virus on ER stress has been the focus of several studies. 
Indeed, it was found that IAV infection of primary tracheal epithelial cells of mice activated 
ATF6 and increased ERp57, but not CHOP-10 [314]. ERp57 is known to be involved in 
folding of hemagglutinin (HA) protein of influenza [315]; therefore, its upregulation might 
be favorable for influenza virus replication. Viruses rely heavily on cellular machinery for 
their replication. Therefore, unlike the induction of ERp57, induction of CHOP-10 might 
be detrimental to the virus replication. Thus, it is intuitive to speculate that influenza 
viruses might possess mechanisms to inhibit expression/activation of CHOP-10. Whether 
influenza virus infection inhibits the expression of CHOP-10 in IL-23 secreting cells such 
as macrophages is not known and needs to be investigated. NS1 is a multifunctional protein 
of influenza virus that has been shown to interact with viral RNP complex [316] and is 
important in viral replication and selective enhancement of viral mRNA translation [317, 
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318]. Influenza NS1 protein has also been shown to inhibit the induction of important host 
antiviral proteins- the type-I IFNs. Influenza virus NS1 protein, therefore, seems to be a 
suitable candidate for the viral factor involved in the modulation of the ER stress response 
pathway. Whether influenza virus infection inhibits the expression of CHOP-10 in IL-23 
secreting cells such as macrophages is not known and needs to be investigated. 
2.13. Equine influenza virus 
 Equine Influenza is a common respiratory viral disease of equids caused by IAV. 
Based on the reactivity of the HA and NA surface proteins, equine influenza viruses (EIV) 
have been divided into two subtypes, H7N7 and H3N8 respectively. Of the two EIV 
subtypes, only the H3N8 subtype is currently in the circulation and responsible for 
outbreaks of the disease and is endemic to the equine population in the United States and 
most of the world [319]. The disease is highly contagious and after an incubation period of 
1-3 days the clinical picture is characterized mainly by high fever, a serous nasal discharge, 
dry, harsh nonproductive coughing and swelling of the submandibular lymph nodes [320]. 
Equine influenza itself is generally non-fatal except in donkeys [321] and mildly affected 
animals recover within 2-3 weeks. However, in severely affected horses it may take up to 
six months. Secondary bacterial infections such as Streptococcus zooepidemicus, 
Pasteurella and Actinobacillus spp. [322] often complicate the disease. In cases of 
secondary bacterial infections a second febrile response that is generally higher and of 
longer duration, typically develops 2-3 days after initial fever. In such cases nasal discharge 
becomes mucoid to mucopurulent; coughing and respiratory distress are more pronounced, 
and if untreated could lead to severe bronchopneumonia that could be fatal. Exercise and 
training need to be stopped as they could reduce the rate of recovery. Lost training and 
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performance due to influenza, therefore, heavily influence the economy of the equine 
industry. Secondary bacterial pneumonia may further delay the recovery and contribute 
even more to the losses due to equine influenza. Significant improvements, since the 
discovery of the virus, have been made in understanding the pathobiology of the virus and 
development of vaccines. However, despite the regular use of vaccines, outbreaks of equine 
influenza continue to occur [323, 324]. Thus, research on novel preventive and therapeutic 
interventions is highly sought after. 
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CHAPTER 3 
Modulation of endoplasmic reticulum stress pathway by influenza virus 
3.1. Introduction 
Influenza A virus is the etiological agent of one of the most common respiratory 
diseases of birds and mammals that results in seasonal epidemics as well as occasional 
pandemics with significant mortality and economic losses. Each year, seasonal influenza 
epidemics result in 3-5 million severe cases and 250,000-500,000 deaths worldwide. In 
United States alone, influenza virus infection is estimated to result in 226,000 
hospitalizations and 36,000 deaths [325, 326]. Antivirals such as neuraminidase inhibitors 
and M2 ion channel inhibitors have been used in the past with limited success. Thus annual 
vaccination is currently the most preferred method for control of influenza. Current 
vaccines for seasonal influenza are based on predicting the vaccine strain on the basis of 
surveillance data and carry an inherent risk of failure. Additionally, with current 
technology it would be difficult to prepare large amounts of vaccines in a limited time. 
Pathogenesis of influenza involves a complex interplay of host and viral factors. Despite 
decades of research there are still unresolved areas in the interaction of host cells and 
influenza virus. Further understanding of influenza virus and the host cell would be a 
valuable resource in developing new therapeutic and preventive modalities. The current 
study was designed to understand the interplay between influenza virus and the cellular ER 
stress response of host. 
 The ER stress response, also known as unfolded protein response (UPR), is an 
evolutionary conserved molecular cascade that helps to maintain ER homeostasis and 
protein folding capacity during ER stress. However, recent advances in the field suggest a 
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broader range of effects of ER stress response in multiple cellular and disease processes 
such as apoptosis, inflammation, and metabolism [327-333]. In mammalian cells IRE1, 
PERK and ATF6 are the sensors of ER stress that initiate downstream signaling events to 
reduce the protein load on the ER and the ER chaperone immunoglobulin heavy-chain 
binding protein (BiP) also known as glucose-regulated protein 78 (Grp78) acts as a master 
controller [334-336]. Activated IRE1 has endoribonuclease activity, and it performs 
alternative splicing of XBP-1 mRNA production of the active XBP-1 transcription factor 
[311, 312]. Active XBP-1 then translocates to the nucleus and promotes transcription of 
ER chaperone genes that are involved in ER protein folding. ATF6 is an ER resident 
transmembrane protein which in the event of ER stress activates transcription of UPR target 
genes including chaperone proteins. Activation of PERK leads to phosphorylation of eIF-
2α at serine 51 that leads to the inhibition of general protein synthesis to reduce the protein 
overload in the ER [337].  
 Since viruses rely heavily on the host cell protein synthesis machinery, the 
functional status of the ER may significantly affect viral replication and pathogenesis.  For 
example, influenza virus uses ER chaperone protein Erp57 for the folding and maturation 
of HA protein [315]. Therefore, differential regulation of ER stress could be important in 
the pathogenesis and replication of viruses [3]. Differential activation of ER stress response 
pathways has been reported for multiple virus [3, 314, 338]. Although differential 
regulation of the ER stress response by influenza virus has been shown in tracheal epithelial 
cells [314, 338], ER stress response of macrophages, important in the pathogenesis as well 
as control of influenza virus, has not been investigated. Moreover, viral factors involved in 
the differential activation of ER stress response have not been investigated.  
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CHOP-10, a key mediator of ER stress response, is a potent inducer of apoptotic cell death 
[339]. Influenza virus lacking NS1 (delNS1), as compared to the wild type virus, has been 
reported to induce significantly higher apoptosis. Therefore, the study was designed to test 
the hypothesis that influenza virus NS1 protein is responsible for differential activation of 
ER stress response and inhibits the expression of CHOP-10 in mouse macrophage. The 
hypothesis was tested using recombinant influenza virus lacking NS1 (delNS1) otherwise 
isogenic to PR8 virus, and Newcastle disease virus (NDV) engineered to express NS1 
protein of PR8 virus. The results of study suggest that NS1, at least in part, mediates the 
inhibition of CHOP-10.     
3.2. Materials and methods 
RAW264.7 Cells: RAW264.7 cells (RAW hereafter) were used as a surrogate for murine 
AM. To make sure the observed results are not due to altered physiology due to culture 
conditions RAW cells used in the study were obtained from two different sources (ATCC 
and a kind gift from Dr. S. Straley at University of Kentucky). Cells were cultured in 
growth medium (RAW-GM) (high glucose (4.5g/L) and low sodium bicarbonate (1.5 
gm/L) containing DMEM- supplemented with 10% fetal bovine serum (Hyclone) and 
penicillin-streptomycin solution (CellGrow) to give a final concentration of 100 I.U. 
penicillin and 100 μg/mL. For the subculture, cells were gently scraped with a cell scraper 
and resuspended in RAW-GM for seeding at appropriate density into the new culture 
vessels. For in vitro infection experiments, after inoculation cells were cultured in high 
glucose and low bicarbonate DMEM supplemented with 0.35% BSA and 1ug/mL trypsin 
(Sigma) (RAW-SFM). 
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 For the mRNA expression studies, 1x106 cells were seeded in 12 well tissue culture 
plates in duplicate/treatment and incubated overnight at 37○C/5% CO2. Before infection 
cells were washed three times with pre-warmed phosphate buffered saline (PBS, pH 7.4) 
and inoculated with virus as desired multiplicity of infection (MOI) in 200uL final volume 
of inoculum. Virus was allowed to adsorb for 1hr at 37○C/5% CO2. After adsorption, cells 
were washed three times in pre-warm PBS to remove unabsorbed virus. Cells were then 
fed with pre-warmed RAW-SFM containing 1ug/mL trypsin and incubated for the desired 
time at 37○C/5% CO2. 
Viruses: Wild type and recombinant PR8 virus lacking NS1 gene (delNS1) generated by 
reverse genetics (obtained from Dr. Peter Palese and has been described previously [276]). 
This virus replicates efficiently only in substrate or hosts deficient in the type-1 IFNs (IFN-
α/β), therefore the viruses were grown in Vero cells that lack type-I interferon signaling. 
Vero cells were cultured in DMEM containing 10% fetal bovine serum (Hyclone) and 1X 
PSA solution (CellGrow) at 37○C/5% CO2. For virus isolation cell were seeded in roller 
bottles and medium was supplemented with HEPES (CellGrow) at 20mM final 
concentration. After inoculation with virus, cells were cultured in DMEM supplemented 
with 0.35% bovine serum albumin (BSA), 1X PSA solution (CellGrow), HEPES at 20mM 
and 1ug/mL trypsin (Sigma). After 48 hrs cell culture supernatant was collected and 
clarified by centrifuging at 3000 RPM for 30 min at 4○C. Clarified virus was further 
concentrated by pelleting at 26000g for 2hrs at 4○C over 25% sucrose cushion. After 
centrifugation the supernatant was removed and pellet was resuspended in DMEM 
supplemented with 5% glycerol and stored at -80○C in single use aliquots. Viral titer was 
determined by performing TCID50 titer analysis in Vero cells. 
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Recombinant B1 vaccine strain of Newcastle disease virus expressing NS1 of PR8 
virus (NDVB1-NS1) and parent virus (NDVB1) were a kind gift from Dr. Adolffo Garcia-
Sastre (Mount Sinai, NY). Recombinant NDV viruses were generated by reverse genetics 
as described previously [340]. Design of the NDV constructs is given in figure 3.1. The 
viruses were grown in the 10 day old chicken embryos and allantoic fluid was harvested 
48 hrs after inoculation. Allantoic fluid was clarified by centrifugation at 3000RPM for 30 
min at 4○C. Virus was distributed as single use aliquots and stored at -80○C. EID50 titer 
was determined following method the method of Reed and Meunch [341]. 
RNA extraction and Real-time PCR: Total cellular RNA was extracted using Purelink® 
RNA mini kit (Life Technologies) with on column DNase digestion using Purelink® 
DNase (Life Technologies). At the desired time point, media was removed from the wells 
and cells were washed once with PBS. Cells were lysed in the wells with 600uL of RNA 
lysis buffer supplied with the kit. Cell lysates were homogenized using shredder columns 
(Qiagen) followed by RNA extraction protocol with on column DNase digestion supplied 
with the Purelink® RNA mini kit (Life Technologies). Total cellular RNA concentration 
and purity was determined by UV spectrophotometry using Nanodrop™ and a total of 1µg 
total RNA was reverse transcribed using high capacity RNA-to-cDNA© kit (Life 
Technologies) following protocol supplied by the manufacturer. Relative mRNA 
expression of the markers of different ER stress pathways (Table 3.1) was analyzed by 
quantitative real-time PCR using commercially available pre-validated Taqman© assays 
(Applied Biosystems) and Taqman® Universal Master Mix II no UNG (2X) (Applied 
Biosystems) following manufacturers recommendations.  Briefly, 20 µL cDNA was diluted 
to a final volume of 100 µL and a 4.5 µL cDNA was used in real-time PCR reaction with 
 
51 
  
a final volume of 10uL with 1X final concentration of Taqman® assay and mastermix. 
Each sample was run in duplicate on ABI 7900HT sequence detection system (Applied 
Biosystems) following the standard protocol suggested by the assay manufacturer. 
Amplification data was exported to LinregPCR [342] for the calculation of efficiency of 
real-time PCR reactions. LinReg PCR efficiency calculations were based on the slope of 
linear regression line containing 4-6 data points. For relative quantitation, only the 
reactions with efficiency ranging between between 2± 0.2 (2 =100% efficiency) and R2 
(squared correlation coefficient) greater than 0.98 were used for data analysis. Relative 
expression was analyzed by the ΔΔCT method [343]. Murine GAPDH was used as an 
internal control and mock infection was used as a calibrator for relative expression analysis. 
Western blotting: For immunoblotting, 5x106 RAW264.7 cells were plated in a 60 mm 
tissue culture dish and incubated overnight. Cells were infected with the respective viruses 
at a MOI of 2 TCID50/cell as described above. Two sets of cells were mock inoculated. 
While one of the mock inoculated cells served as negative control, the second one was 
treated with 0.025uM Thapsigargin (TG, T-7459, Life Technologies)   for 12 hrs and served 
as positive control. At 20 hrs PI cells were washed twice with cold Ca++ and Mg++ free PBS 
(pH 7.4) and cells were harvested by gentle scraping. Scraped cells were resuspended in 
cold PBS and centrifuged at 600g/5min at 4οC. The Supernatant was carefully removed, 
and cells were lysed by resuspending in 200 µL RIPA lysis buffer (Santacruz 
biotechnology) supplemented with Halt protease and phosphatase inhibitor cocktail™ 
(ThermoScientific Pierce) at 1X final concentration following manufacturer’s 
recommendation. Cells were kept on ice during lysis. Total cell lysates were clarified by 
centrifuging at 16000g/5 min 4οC. Total cell protein obtained was transferred to 1.5 ml 
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microcentrifuge tubes as single use aliquots. Protein concentration was determined using 
the BCA protein assay kit© (Thermoscientific Pierce) using the microplate procedure 
supplied with the kit. For immunoblotting, approximately 30 µg of whole cell protein was 
diluted 1:5 in denaturing protein loading buffer supplemented with protease inhibitors and 
boiled for 5 min at 95 οC, cooled and then loaded for electrophoretic separation. Proteins 
were separated by electrophoresis on 12% polyacrylamide gels (Laemmli, 1970), and 
subsequently transferred to nitrocellulose membranes by semi-dry electrophoretic transfer 
in Tris-glycine buffer (pH 8.3). The membranes were blocked for 1hr with PBS containing 
5% non-fat dry milk (NFDM), 5% normal goat serum (NGS), and 0.05% Tween 20, 
followed by primary antibody (anti-Influenza NP (Fitzgerald, Concrod, MA) and anti-
murine CHOP-10 (Santacruz biotechnology)) incubation for overnight at 4 0C in PBS 
containing 0.1% normal goat serum (Sigma) and 0.1% nonfat dry milk (Carnations, 
Nestle). After multiple washes, the membranes were incubated with peroxidase-conjugated 
anti-rabbit (IgG-HRPO) secondary antibody (Jackson Immunoresearch Labs, Inc.) for 1 hr. 
The membranes were then washed and incubated with Supersignal substrate (Pierce, 
Rockford, IL, USA) for chemiluminescence detection, and visualized with a FluorChem 
8800 imaging system (Alpha Innotech, San Leandro, CA). 
Immunofluorescence assay: Indirect double immunofluorescence staining was used to 
localize CHOP-10 and the influenza virus NP protein. For the immunofluorescence assay, 
1x106 cells were seeded into the 12-well tissue culture plates with coverslip inserts. Cells 
were infected with either PR8 or delNS1 virus at MOI of 2 TCID50/cell. For a negative 
control, cells were mock infected with medium alone and for a positive control of CHOP-
10, mock-infected cells were treated with 0.025uM TG during last 7 hrs of infection. At 20 
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hrs PI, cells were rinsed twice with cold PBS and then fixed with 4% paraformaldehyde 
for 10 min at room temperature. After washing once with cold PBS, cells were 
permeabilized with 0.2% Triton X-100 (Sigma) in PBS for 10 min at room temperature. 
Nonspecific antibody-binding sites were blocked by incubation of cells with 10% normal 
goat serum (Sigma) in PBS for 1hr. Mouse monoclonal primary antibody against influenza 
virus NP protein (Fitzgerald, Concord, MA) and polyclonal rabbit antibody against murine 
CHOP-10 (SC-575, Santacruz Biotechnology) were diluted in blocking solution at 1:100 
and 1:50 dilution, respectively and reacted with cells for 1hr at room temperature. After 
washing three times for 5 min each wash, cells were incubated at room temperature for 30 
min with FITC-conjugated goat anti-mouse IgG antibody (Pierce, Rockford, IL) and Texas 
red conjugated goat anti-rabbit IgG antibody (1:400 dilution in blocking buffer). Cells were 
washed three times with PBS, and then coverslips were carefully blotted to remove excess 
liquid. A small drop of Vectashield H-1200 (Vector labs) anti-fade medium containing 
DAPI was placed on the coverslips and coverslips were mounted on to clean glass slides. 
Slides were examined using Zeiss Axioplan-2 fluorescence microscope and images were 
captured with cytovision /Genus™ software application. 
Statistical analysis: Statistical analysis of data was performed by one way ANOVA, and 
means of treatment groups were compared using Fishers least significant difference test 
using GraphPad (Prism6.0) software.  
3.3. Results 
NS1 inhibits expression of BiP/Grp78 (Hspa5): BiP/Grp78 has been suggested as the 
master regulator of the ER stress pathway therefore effects of influenza virus 
NS1expression on the induction of BiP were studied first. The hypothesis was that NS1 
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inhibits the ER stress response. So we expected that virus lacking NS1 (delNS1 and 
NDVB1) will induce a higher expression of BiP as compared to the respective parental 
viruses.  In order to determine the role of NS1 on BiP mRNA expression, RAW cells were 
infected either with PR8 virus or delNS1 and either with NDVB1 virus or NDVB1-NS1 
virus at MOI of 2TCID50/cell. Cells were incubated at 37 C/5% CO2 for 20 hrs after 
infection. Two sets of cells were mock infected to serve as controls. TG is a competitive 
inhibitor of Sarco/endoplasmic reticulum Ca++ [344] and a potent inducer of ER stress. 
Thus, one set of mock-infected cells was treated with TG (0.025uM) for the last 7 hrs of 
incubation to serve as a positive control, while mock-infected cells were used as a negative 
control and calibrator for relative expression analysis. Results of BiP mRNA expression 
are presented in Fig 3.2. Being a potent inducer of ER stress TG, as compared to all other 
treatments, induced significantly higher expression of BiP mRNA(P<0.0001). While 
relative expression of BiP mRNA in the delNS1 virus treated cells was significantly higher 
than the PR8 virus (P<0.0097), it did not differ significantly from the mock-infected cells. 
Relative expression was significantly lower in the PR8 virus infected cells (P= 0.0114) as 
compared to the mock-infected cells, as well as TG treated cells. These results suggest that 
virus infection resulted in the inhibition of ER stress, however it was more pronounced in 
the wild type PR8 virus. When compared to the mock-infected cells, neither NDVB1 nor 
NDVB1-NS1 showed any significant difference (P>0.05). However, relative expression of 
BiP mRNA was significantly lower in the NDVB1-NS1 infected cells as compared to the 
NDVB1 infected cells (P= 0.0312). Together these data suggest that influenza virus 
NS1protein causes downregulation of BiP protein in the RAW264.7 cells.  
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Effect of NS1 on IRE1 Pathway: The IRE1 mediated branch of ER stress response was 
evaluated by determining the relative expression of total XBP1 (unspliced) mRNA 
expression as well as by determining the relative expression spliced form of XBP1 mRNA 
in cells treated as above. Results are presented in Fig 3.3.  As compared to all other 
treatments, TG treated treatment resulted in a significantly higher expression of total as 
well as spliced XBP1 mRNA (P<0.0001). DelNS1 virus induced a significantly higher 
expression of Total XBP1 mRNA as compared to the PR8 infected (P = 0.0056) or mock 
infected cells (P =0.005), suggesting that NS1 does inhibit XBP1 mRNA expression. 
However, neither PR8 nor mock cells showed a significant difference in the mRNA 
expression of spliced XBP-1. Although statistically not significant (P= 0.0507), expression 
of spliced XBP-1 mRNA was approximately two-fold higher in the cells infected with 
delNS1 virus as compared to the PR8 virus infected cells. As compared to the mock-treated 
cells, both NDVB1 and NDVB1-NS1 induced significantly higher expression of total XBP 
(P=0.0031 and 0.0079, respectively). While NDVB1, as compared to the mock-treated 
cells, showed significantly higher expression of spliced XBP1 mRNA (P=0.0344), there 
was no significant difference in the expression of spliced XBP1 mRNA between NDVB1-
NS1 and mock-treated cells (P=0.1361). These results indicate that influenza virus NS1 
inhibits the IRE1 pathway of ER stress response by inhibiting the endoribonuclease activity 
of IRE1, as well as downstream mediator XBP-1. 
Effect of NS1 on ATF6 pathway: Expression of chaperone genes such as ERDJ3, GRP94 
and ERP72, at least partly, depend on ATF-6 for their full upregulation [345, 346]. 
Therefore, to investigate ATF6 activation, mRNA expression of chaperone genes was 
analyzed. Results of this experiment are presented in fig 3.4. DelNS1 virus, as compared 
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to the PR8 virus, induced significantly higher expression of chaperone genes ERDJ3 
(P=0.0029) and GRP94 (P=0.047). However, PR8 virus, as compared to delNS1 virus, 
induced significantly higher expression of ERP72 (P<0.0029). While expression of ERDJ3 
and GRP94, were lower in the PR8 virus infected cells (P=0.0003 and 0.0015, 
respectively); expression of ERP72 mRNA was significantly higher (P<0.0003) in the PR8 
infected cells as compared to the mock-infected cells. There was no significant difference 
in the expression of chaperone genes between NDVB1 and NDVB1-NS1 viruses (P= 
0.1447, 0.1079, 0.1447 for ERDJ3, GRP94 and ERP72, respectively). These data suggest 
that influenza virus differentially regulate the expression of ATF-6 pathway that may 
involve NS1 mediated as well as NS1 independent mechanisms. 
Effect of NS1 on PERK pathway: Activation of the PERK pathway leads to selective 
enhancement of CHOP-10 transcription; therefore to analyze the PERK pathway, mRNA 
expression of CHOP-10 was examined in cells treated as above. Results are presented in 
Fig 3.5. Cells treated with TG showed a significantly higher expression of CHOP-10 
(P<0.0001), as compared to all other treatments including mock and virus infections. While 
delNS1 virus, as compared to the PR8 virus, induced significantly higher expression of 
CHOP-10 (P=0.456), there was no significant difference in the expression of CHOP-10 
between NDVB1 and NDVB1-NS1 infected cells (P=0.1029). However, expression of 
CHOP-10 was approximately two-fold lower in the NDVB1-NS1 infected cells, as 
compared to the NDVB1 infected cells (mean relative expression 6.815 and 3.275, 
respectively). DelNS1 infected cells showed approximately five-fold higher expression of 
CHOP -10, as compared to the mock-infected cells (mean relative expression 4.93 and 1, 
respectively). On the other hand, expression of CHOP-10 was approximately three-fold 
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lower in the PR8 infected cells as compared to the mock-infected cells (mean relative 
expression 0.3 and 1, respectively). 
 Differences in the CHOP-10 expression levels between PR8 and delNS1 virus 
infected cells were also reflected on the protein levels. Western blotting was performed on 
total cellular protein from the cells treated as above.  Western blotting was performed using 
anti-CHOP -10 antibody (SC-575, 1:250 dilution, Santacruz Biotechnology) and anti-actin 
(1:1000 dilution, cell signaling technology) was used as loading control antibody. Results 
are presented in Fig 3.6. In the TG treated cells as well as delNS1 infected with delNS1 
virus, higher levels of CHOP-10 protein were detected. On the other hand, CHOP-10 
protein was barely detectable in the PR8 virus or mock infected cells. During the ER stress 
response, once activated CHOP-10 translocates to the nucleus where it activates 
transcription of other genes that have CCAT elements. Therefore, translocation of CHOP-
10 was examined using double immunofluorescence using anti-CHOP-10 (SC-575) and 
anti-influenza NP antibodies in the delNS1 virus and PR8 virus infected cells. Mock 
infected cells were used as a negative control, and TG treated cells were used as a positive 
control. IFA analysis revealed that there was no detectable level of CHOP-10 in PR8 
infected cells (Fig 3.7). On the other hand, delNS1 infected cells did show expression of 
CHOP-10 that was mainly localized in the nucleus. Taken together these data suggest that 
influenza virus inhibits the activation of PERK pathway. Furthermore, inhibition of CHOP-
10, at least in part, is mediated by NS1. 
3.4. Discussion 
 In the recent years, the ER stress response has emerged as a critical player in the 
pathogenesis and replication of viral infections and several groups have reported a 
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differential regulation of ER stress response pathway by viruses including influenza [3, 
314, 338]. One of the earliest reports on ER stress linking to influenza showed that 
overexpression of a mutated, misfolded form of influenza HA protein induces ER stress in 
the simian cells [347]. Recently, differential activation of UPR pathways by influenza virus 
infection was investigated in murine tracheal epithelial cells [314] and human 
tracheobronchial epithelial cells [338]. Macrophage cells have been implicated in the 
pathogenesis [299] as well as in protection [348] from influenza virus; hence activation of 
ER stress pathway in these cells may play a critical role in the pathogenesis of influenza. 
Therefore, the current study was designed to examine the ER stress pathway in influenza 
virus infected macrophage cells. Furthermore, this study, to best of my knowledge, also 
appears the first to examine the role of viral NS1 protein in the ER stress response pathway. 
ER stress-induced transcription factor CHOP-10 has been shown to induce apoptosis as 
well as regulate the expression of certain cytokines such as IL-23 [4] and thus may have 
important implications in the replication, pathogenesis and immune response against 
influenza. Therefore the focus of this study was CHOP-10. 
 Overall, it was found that in murine macrophage cell line RAW264.7, influenza 
virus infection resulted in inhibition of the IRE1 as well as PERK pathway. We also 
observed that PR8 virus resulted in slight activation of ATF6 pathway with the exception 
of chaperone protein ERP72 that was significantly upregulated by PR8 virus. Preferential 
activation of the ATF6 pathway was also observed in murine tracheal epithelial cells where 
influenza infection resulted in activation of ATF6 and an increase in ERp57 but not CHOP-
10 [314]. However, in contrast to the present study, in HTBE cells, influenza virus 
activated the IRE1 pathway with little or no concomitant activation of PERK or ATF-6 
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pathway [338]. These differences might be explained by the differences between cell 
systems and time points for ER stress analysis. Macrophage cells are potent APCs and 
secretory cells thus these might be more adept at handling the protein overload as compared 
to the epithelial cells; thus macrophages cells may be more resistant to ER stress. 
Furthermore, Hassan et al., [338] studied the ER stress response at early time point (12 hrs) 
but present study and study by Roberson et al., [314] analyzed the ER stress marker 
expression at later time point (20 hrs or later).  
 Most of the ER chaperone proteins depend on induction of the ATF-6 pathway, 
therefore it is conceivable that up-regulation of chaperones might be crucial for viral 
replication by preventing severe ER stress and eventual cell death. ERp57, a member of 
protein disulfide isomerase (PDI) family of protein, is critical in the folding of influenza 
virus HA [315]. ERp72 is also a member of PDI family of proteins and closely related to 
ERp57. Therefore, upregulation of ERP72 might help in viral protein folding. Inhibition of 
the ER stress response was reported to be critical in influenza viral replication.  
Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, has been shown to 
possess molecular chaperone properties, and to alleviate ER stress response in vitro as well 
as in vivo [332]. Restoration of the ER stress response using treatment of cells with 
TUDCA, prior to influenza virus infection of HTBE cells resulted in significantly lower 
titers of influenza virus as compared to the TUDCA non-treated control cells. While viral 
RNA replication was not affected, there was markedly reduced viral protein synthesis in 
TUDCA treated cells as compared to the non-treated cells, suggesting that influenza virus 
required an impaired ER stress response for efficient viral replication [338]. Differential 
activation of ER stress pathways has also been reported in other viruses. While hepatitis C 
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virus induces the ATF6 pathway but blocks the IRE1 pathway [349], hepatitis B virus 
induces ATF6 and IRE1 but not PERK [350]. As African swine fever virus (ASFV) uses 
ER as a site for the assembly and maturation it is expected to induce ER stress, however, 
in ASFV-infected cells, it did not induce activation of PERK pathway [351]. Currently, the 
only known mechanism of activation of PERK, ATF6, and IRE1 is their release from BiP. 
The mechanism behind differential activation of the different arms of the UPR is unknown 
[3]. 
 Activation of PERK leads to the phosphorylation of eIF2α that results in host 
protein shutdown to resolve the ER stress. Phosphorylation of eIF2α, however, results in 
preferential translation of ATF4 that activates downstream targets, including CHOP-10. 
Induction of CHOP-10 and the consequent apoptosis might play a critical role in the 
development of viral cytopathic effects, viral spread and pathogenesis. For example, UPR 
was associated with induction of apoptosis in virus infected cells in Japanese encephalitis 
virus [352], bovine viral diarrhea virus [353], tula virus [354], severe acute respiratory 
syndrome coronavirus (SARS-CoV) [355]), and West Nile virus [356]).   
 In the present study, we found that influenza virus, although induced ER-associated 
chaperone, did not induce CHOP-10. Further analysis of delNS1 virus and PR8 virus 
revealed that NS1 protein was involved in the inhibition of CHOP-10 expression and 
activation. Similar to our finding, AFSV, an ER tropic virus that was expected to induce 
CHOP-10, was found not to inhibit induction and activation of CHOP-10 [351]. Although, 
induction CHOP-10 and consequent host cell death by apoptosis may help in viral 
pathogenesis, it may also affect the viral replication. Therefore, viruses might have evolved 
with the mechanism to regulate the induction of ER stress associated apoptosis to facilitate 
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their replication. In support of our hypothesis, a recent study found that although influenza 
virus-induced ATF6 pathway it did not induce CHOP-10 [314].  
 Comparison of expression of ER stress response markers in wild type and mutant 
virus either lacking NS (PR8 vs. delNS1) or expressing NS1 (NDVB1 vs. NDVB1-NS1) 
suggests that NS1, at least in part, plays some role in the differential activation of ER stress 
pathway. Moreover, higher expression of ERP72 was present in the viruses that expressed 
NS1 protein (PR8 and NDVB1-NS1) suggesting that the NS1 protein might participate in 
differential upregulation of ERp72. Moreover, influenza virus lacking NS1 (delNS1) have 
been reported to induce apoptosis earlier as compared to the wild type virus  [195]. 
Therefore, it seems possible that influenza virus NS1 protein might be the viral factor 
involved in the inhibition of CHOP-10. In conclusion, our results support the hypothesis 
that influenza virus infection results in a differential activation of UPR pathway that, at 
least in part, may be dependent on the NS1 protein of influenza virus. 
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Table 3.1: List of Taqman® assays used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Other name Taqman ®Assay ID 
BiP Hspa5 Mm00517690_g1 
ERP72 Pdia4 Mm00437958_m1 
ERdj3 Dnajb11 Mm00518196_m1 
GRP94 Hsp90b1 Mm00441926_m1 
XBP-1 (U) XBP1 unspliced  Mm00457357_m1 
XBP-1 (S) XBP1 spliced Mm03464496_m1 
CHOP-10 DDIT3, Gadd153 Mm01135937_g1 
GAPDH GAPD Mm99999915_g1 
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Figure 3.1: Schematic representation of NDVB1 and NDVB1-NS1 constructs 
 Adapted from: Park M et al. J. Virol. 2003; 77: 9522-9532 
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Figure 3.2: Effect of influenza virus on BiP/GRp78 mRNA expression 
Data are presented as mean ± SD and are representative of at least two independent 
experiments carried out in duplicate. 
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Figure 3.3: Effect of influenza virus on XBP1 mRNA expression 
Data are presented as mean ± SD and are representative of at least two independent 
experiments carried out in duplicate. 
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Figure 3.4: Effect of influenza virus on ATF6 pathway  
Data are presented as mean ± SD and are representative of at least two independent experiments carried out 
in duplicate. 
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Figure 3.5: Effect of influenza virus on expression of CHOP-10 mRNA 
Data are presented as mean ± SD and are representative of at least two independent 
experiments carried out in duplicate. 
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Figure 3.6: Effect of influenza virus on expression of CHOP-10 protein  
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Figure 3.7: Effect of influenza virus on activation of CHOP-10 
Nucleus is stained with DAPI (Blue), Influenza virus nucleoprotein detected with FITC 
conjugated secondary antibody (green) and CHOP-10 detected with Texas red conjugated 
secondary antibody. 100X magnification. 
 
C
o
p
y
rig
h
t ©
 A
sh
ish
 T
iw
ari 2
0
1
4
 
 
 
70 
  
CHAPTER 4 
Influenza A virus NS1-mediated inhibition of CHOP-10 downregulates IL-23  
4.1. Introduction 
 Influenza virus is a negative-sense single-stranded RNA genome-carrying virus 
that causes one of the major respiratory diseases worldwide. Recent epidemiological and 
laboratory studies provide a strong evidence that secondary bacterial pneumonia is the 
major cause of death during influenza [209]. With emerging drug-resistant strains of both 
influenza virus and bacteria, along with the looming threat of pandemic influenza, alternate 
therapeutic measures become important. Pathogenesis of influenza virus depends on 
intricate interaction of viral and host cellular factors, and the host innate immune responses. 
Thus understanding these interactions would be important in identifying new therapeutic 
targets. 
 IL-23 is a recently identified member of IL-12 family of heterodimeric cytokines 
that is essential for proliferation of IL-17 producing Th17 cells. IL-17 has been shown to 
induce other cytokines that help recruit other critical cells such as macrophage, monocytes 
and neutrophils. IL-23/IL-17 mediated immune responses have been implicated in control 
of a variety of respiratory bacteria [279], however, its role during influenza virus infection, 
especially in the setting of bacterial co-infection, has just begun to be appreciated. In a 
recent study, Kudva et al., reported that influenza virus-induced type-I IFN resulted in 
inhibition of IL-23/IL-17 that caused increased susceptibility of the host to secondary 
bacterial infection [300]. However, influenza virus is known to inhibit type-I IFN response. 
Thus, there is a possibility that another mechanism might be involved in the influenza virus 
mediated inhibition of IL-23.   
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 Multiple cellular transcription factors have been proposed to control the regulation 
of IL-23, including CHOP-10 [4]. In previous experiments (Chapter III) influenza virus 
was found not to induce the expression of CHOP-10. Therefore, considering these factors, 
it was hypothesized that influenza virus NS1 mediated CHOP-10 inhibition results in the 
downregulation of IL-23/IL17 pathway. In order to test this hypothesis, expression of IL-
23 was studied in vitro in murine macrophages as well as in vivo in a influenza mouse 
model.  
4.2. Materials and methods 
Cells: Vero cells and RAW264.7 cells were cultured as described in the previous chapter. 
Mouse primary alveolar macrophage cells (AM) were isolated and purified by a method 
described previously [357] with minor modifications. Briefly, 6-8 week old female 
c57BL/6 mouse (Harlan) was euthanized by intraperitoneal injection of 200 µL 
Buthanasia-D™. Mouse was then sprayed with 70% ethanol, and the abdominal cavity was 
carefully opened to bleed the mouse by severing abdominal aorta. Trachea was exposed 
aseptically, and a small puncture was made with a sterile needle to insert a sterile catheter 
made in-house using 20G Tygon® tubing. Catheter was attached to a three-way valve 
connected to two 5cc syringes. One ml warm PBS (37○C) was infused through the trachea 
with one syringe then the inlet valve was closed. The outlet valve was then opened and 
while gently massaging the thoracic cavity fluid was aspirated into the second syringe. 
After this, the valve was switched to the inlet syringe, and the process was repeated for a 
total of 5 mL PBS. The BAL fluid thus obtained from several mice was pooled and 
centrifuged at 400g/10 min at 4○C to pellet the cells. If BAL cells were contaminated with 
red blood cells (RBC), the cell pellet was resuspended in 1ml ACK lysing buffer (Gibco) 
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for 30 sec to lyse the RBC then washed again with PBS. The Cell pellet was resuspended 
in RPMI-1640 (Invitrogen) medium supplemented with 10% FBS and 1X PSA solution 
(AM-growth medium). Cell concentration was determined using a hemacytometer and 
adjusted to 1x106/mL in AM-growth medium. In order to obtain pure population of alveolar 
macrophages, BAL cells were plated in 100 mm tissue culture dishes and incubated at 
37○C/5% CO2 for two-four hours with gentle rocking at every hour. After incubation, the 
plate was gently rocked and tilted to collect aspirate medium containing unattached 
lymphocytes and other cells. Attached cells are then washed once with growth medium and 
then scraped, counted and seeded into desired culture vessels as per requirement of the 
experiment. After adherence step, the cells are usually in ≥90% pure population of 
macrophage and this method usually yields approximately 3-5x105 AM cells /mouse [357]. 
Infectious agents: PR/8/34 strain (PR8) of IAV and an isogenic recombinant virus lacking 
NS1 (delNS1) as described in the previous chapter (chapter III) were used in the current 
study.  
 For the bacterial infection, Streptococcus zooepidemicus (S. ze) strain 7e was used 
(kind gift from Dr. John Timoney at Gluck Equine Research Center). The bacteria was 
isolated from a clinical case of bronchopneumonia in donkey. One day before mouse 
inoculation, bacteria were freshly streaked on Columbia CNA (Sigma) blood agar 
containing 5% horse blood and incubated for 24 hrs at 37○C/5% CO2. A single isolated 
colony was inoculated in 4 mL Todd-Hewitt broth for 6 hrs to achieve log growth phase. 
After 6 hrs, bacterial culture was pelleted at 6000g/4οC for 20 minutes and then washed 
twice with normal saline. Bacterial pellet was resuspended to 1x108 CFU/mL in normal 
saline. Bacterial concentration was confirmed retrospectively in the inoculum by plating 
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serial dilutions on Columbia CNA (Sigma) blood agar containing 5% horse blood, and 
colonies were counted at 24 hrs after incubation and results were presented as colony 
forming units per mL (CFU/mL). 
Infection of cells with the virus: For the mRNA expression studies in RAW264.7 cells, 
cells were cultured and infected as described in the previous chapter. For mRNA 
expression studies in the primary murine alveolar macrophage, 0.5x106 purified cells were 
seeded in 24 well tissue culture plate and allowed to rest overnight. For infection, cells 
were washed three times with pre-warmed PBS and inoculated with virus at 2 MOI in 
100uL final volume of inoculum prepared in serum free RPMI-1640 (Gibco) supplemented 
with 0.35% BSA (Lampire Biologicals), 1x PSA (CellGrow) and 1ug/mL trypsin (Sigma). 
Virus was allowed to adsorb for 1hr at 37○C/5% CO2. After adsorption, cells were washed 
three times in pre-warm PBS to remove unabsorbed virus. Cells were then fed with pre-
warmed serum free RPMI-1640 supplemented with 0.35% BSA (Lampire Biologicals), 1x 
PSA (CellGrow) and 1ug/mL trypsin (Sigma).  Cells were transferred to the incubator and 
incubated for 20hr at 37○C/5% CO2. 
RNA extraction and Real-time PCR: Total cellular RNA, cDNA synthesis and real-time 
PCR using predesigned validated Taqman® assays (see Table 4.1) and relative expression 
analysis was carried out at described in chapter III.  
Stable expression of CHOP-10: An expression plasmid containing murine CHOP-10 
cDNA under CMV promoter and neomycin resistance as a eukaryotic selection marker was 
purchased from Origene (pCMV-Kan/neo) and used to generate RAW264.7 cells stably 
expressing murine CHOP-10. RAW264.7 cells were transfected using Targafect-RAW 
transfection reagent system (Targeting systems) following protocol supplied with the kit. 
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For the selection of stable clones, 24 hrs after transfection, cell culture medium was 
replaced with growth medium containing 0.6 mg/mL neomycin (G-418, Sigma) and 
continued to be grown with replacing fresh selection medium every two days until 
individual clumps of cells appeared. Individual clumps of the cells were then lifted with 
cell scraper and transferred to separate cell culture dishes and cultured and passaged in 
selection media. Stable clones were screened for expression of CHOP-10 using a Taqman® 
assay as described earlier in this chapter. Stable clones of empty vector were prepared as 
described above and were used as a negative control. 
Lentivirus mediated knockdown of CHOP-10: Commercially available pre-validated 
lentiviral particles for CHOP-10 shRNA and control shRNA were purchased from Sigma. 
Lentiviral transduction was performed following manufacturer’s protocol. Briefly, the day 
before transduction cells were seeded to achieve about 70% confluency on the day of 
transduction. Immediately before transduction the cell culture medium was replaced with 
growth medium containing hexadimethrine bromide (Sigma) at a final concentration of 8 
µg/mL followed by addition of lentiviral particles to achieve MOI of five. Cell culture 
medium was replaced at 24 hrs after transduction and followed by adding selection media 
containing 0.5ug/mL puromycin on the next day. Fresh selection medium was added every 
two days until individual clones of stable cells appeared. Individual clones of the cells were 
then carefully lifted and transferred to the new culture dishes and cultured in selection 
medium until ready for passage. Selection was continued for at least two weeks before 
screening the clones for efficiency of knockdown which was analyzed by real-time PCR 
using Taqman® assay as described earlier in this chapter. 
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Animals: Six-eight week old female c57BL/6 mice were purchased from a commercial 
supplier (Harlan). On arrival, mice were housed in microisolater cages with ad libitum 
supply of food and water. Mice were acclimatized for one week before infection and 
examined daily for any signs of stress or illness following the guidelines of Institutional 
Animal Care and Use Committee (IACUC) at University of Kentucky. All the animal work 
was approved by IACUC at University of Kentucky. 
Inoculation of mice: Mice were sedated with ketamine/xylazine administered 
intraperitoneally. Once sedated mice were held upright by holding from the loose scruff at 
the neck. A small drop of inoculum was placed near each nostril so that mice involuntarily 
inhaled the inoculum. Inoculum was instilled from alternating the nostrils so that whole 
inoculum (60uL) was divided between two nostrils. After inoculation mice were 
transferred back to the microisolater cages with ad libitum supply of fresh food and water 
and observed for recovery. Mice were divided into six independent experimental groups 
with six mice in each group. Experimentally treated groups were housed separately as three 
mice/cage. Details of experimental groups are as following: 
• Control: intranasally inoculated with 60µL normal saline 
• delNS1: intranasally inoculated with 1000 TCID50 units of delNS1 virus in 60µL 
normal saline 
• PR8: intranasally inoculated with 1000 TCID50 units of PR8 virus in 60µL of 
normal saline 
• Zoo: intranasally inoculated with approximately 1x106CFU of S. zooepidemicus 
(strain 7e) in 60µL of normal saline 
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• Zoo+delNS1: intranasally inoculated with 1000TCID50 units of delNS1 virus+ 
approximately 1x106 CFU of S. zooepidemicus (strain 7e) in combined volume of 
60µL of normal saline 
• Zoo+PR8: inoculated with 1000TCID50 units of PR8 virus+ approximately 1x106 
CFU of S. zooepidemicus (strain 7e) in combined volume of  60µL of normal saline 
Bronchoalveolar lavage (BAL) fluid collection: At 12 hrs post infection mice were 
euthanized by intraperitoneal injection of 200µL ButhanasiaD™, and BAL fluid was 
collected aseptically using a sterile intra-tracheal catheter. A total of one mL sterile normal 
saline was instilled in the lungs and aspirated. The aspirated fluid was re-infused and 
aspirated for a total of three times. BAL fluid was centrifuged at 600g/5min, and cell-free 
BAL fluid was transferred to sterile microcentrifuge tube as single use aliquots and frozen 
at -80○C. 
Data Analysis: Results in the RAW cells are presented as mean ±SEM and are 
representative of at least three independent experiments. Results of primary alveolar 
macrophage cells are from a single experiment done in duplicate. Data was analyzed by 
using Prism6 (GraphPad Software). 
4.3. Results 
Effect of influenza virus NS1 on type-I IFN expression: Recently, induction of type-I 
IFN was implicated in the influenza virus mediated inhibition of IL-23. However, influenza 
virus NS1 is known to inhibit the type-I IFN response [172].Thus, before testing my 
primary hypothesis, effect of NS1 on relative mRNA expression of IFN-β was tested in the 
RAW cells as well as in primary alveolar macrophages. Cells were infected either with 
PR8 virus or delNS1 virus at MOI of 2TCID50/cell and incubated at 37 C/5% CO2 for 20 
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hrs after infection. Two sets of cells were mock infected to serve as controls. One set of 
mock-infected cells was treated with TG (0.025uM) and LPS (100ng/mL, Sigma) for last 
7 hrs of incubation to serve as a positive control while mock-infected cells were used as 
negative control and calibrator for relative expression analysis. Murine GAPDH was used 
as internal control for relative expression. Results are presented in Fig 4.1. In RAW cell, 
delNS1 virus, as compared to the PR8 virus induced significantly higher expression of 
IFN- β (P<0.0477). Similarly, in primary AM cells, expression of IFN-β was approximately 
10 fold higher in the delNS1 virus-infected cells as compared to the PR8 virus-infected 
cells. These results indicate that influenza virus NS1 inhibited the expression of type-I IFN, 
as expected.  
Effect of influenza virus NS1 on IL-23p19: IL-23 is a heterodimeric cytokine composed 
of a p40 subunit that is shared with IL-12 and an IL-23p19 subunit that is unique to IL-23 
[279]. Thus, in order to determine the effect of NS1 on IL-23, we analyzed the relative 
expression of IL23p19 in the RAW cells and primary AM cells using total cellular RNA 
from the experiment described above. The underlying hypothesis was that influenza virus 
NS1 inhibits the expression of IL-23p19. Results of relative mRNA expression are 
presented in fig 4.2. Results in the RAW cells are presented as mean ±SEM and are 
representative of at least three independent experiments performed in duplicate. Results of 
primary alveolar macrophage cells are from a single experiment done in duplicate. 
Expression of IL-23p19mRNA, in the RAW cells, was significantly higher in the delNS1 
virus-infected cells as compared to the PR8 virus infected cells (P<0.0446). Also, delNS1 
virus infected AM showed higher relative expression of IL-23p19 as compared to the PR8 
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virus infected cells. These results suggest that influenza virus NS1 inhibits the expression 
of IL-23.  
Effect of Influenza virus NS1 on expression of CHOP-10: CHOP-10 is an ER stress-
induced factor that, in human dendritic cells, has been shown to be critical in the expression 
of IL-23. The hypothesis for this experiment was that Influenza virus NS1 protein inhibits 
the expression of CHOP-10. In order to test this hypothesis, expression of CHOP-10 was 
analyzed in primary AM of mouse and RAW cells were used for the purpose of 
comparison.  Relative expression of CHOP-10 was compared between delNS1 virus and 
PR8 virus infected cells and results are presented in Fig 4.3. Results from the RAW cells 
are presented as mean ±SEM and are representative of at least three independent 
experiments performed in duplicate. Results of primary alveolar macrophage cells are from 
a single experiment done in duplicate. As expected, RAW cells infected with delNS1 virus 
infected cells showed significantly higher expression of CHOP-10 mRNA, as compared to 
the PR8 virus infected cells (P<0.0286). Also, in the AM cells infected with the delNS1 
virus CHOP-10 expression was approximately eight fold higher than the PR8 virus-
infected cells. These results suggest that influenza virus NS1 inhibits the expression of 
CHOP-10. 
Effect of CHOP-10 overexpression on IL-23p19 expression: The hypothesis for this 
experiment was that CHOP-10 overexpression will rescue the inhibition of IL-23 in PR8 
virus infected cells. To test this CHOP-10 was overexpressed in the RAW cells and cells 
were then infected with PR8 virus and expression of IL-23p19 was analyzed. Results of 
this experiment are presented in Fig 4.4. Overexpression of CHOP-10 was confirmed by 
real-time PCR. Expression of CHOP-10 was significantly higher in the expression vector 
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(pCHOP-10) transfected cells as compared to the empty vector (pCMV) transfected cells 
(p<0.0001). Although lower than the mock-infected cells, expression of CHOP-10 was 
significantly higher (P=0.0027) in the PR8 virus infected cells transfected with 
overexpression vector (pCHOP-10+PR8) as compared to the cells transfected with empty 
vector (pCMV+PR8), suggesting that expression of CHOP-10 in the PR8 infected cells 
was restored, at least partially. IL-23p19 mRNA expression was highest in the mock-
infected CHOP-10 overexpressing cells (pCHOP10+Mock). Also, expression of IL23p19 
mRNA was significantly higher (P<0.0001) in the PR8 infected cells overexpressing 
CHOP-10 (pCHOP-10+PR8) as compared to the PR8 infected cells transfected with empty 
vector (pCMV+PR8). These results suggest that restoration of CHOP-10 by plasmid-
mediated overexpression overcomes the influenza virus mediated inhibition of IL-23p19. 
Effect of CHOP-10 knockdown on IL-23: In previous experiments, it was observed that 
delNS1 virus infection of RAW cells and AM led to the induction of CHOP-10 and IL-
23p19 mRNA. Hence, this part of study was designed to investigate whether CHOP-10 
inhibits the induction of IL-23p19 in the delNS1 virus infected cells. To test this, CHOP-
10 was knocked down in the RAW cells by lentiviral-mediated delivery of CHOP-10 
siRNA. Cells were then infected with delNS1 virus and relative expression of CHOP-10, 
and IL-23p19 mRNA was analyzed. Results in the Fig 4.5A confirm the siRNA mediated 
knockdown of CHOP-10. As expected, cells transduced with CHOP-10 siRNA lentivirus 
resulted in significantly lower expression of IL-23p19 as compared to control siRNA 
transduced cells after infection with delNS1 virus (P=0.0019). These results suggest that 
delNS1 virus-induced expression of IL-23p19 is mediated by CHOP-10. 
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Effect of influenza virus NS1 on IL-23/IL-17 pathway in vivo:  The delNS1 virus 
infected cell induced significantly higher expression of both IFN-β and IL-23p19 in vitro 
suggesting that IL-23 expression is not inhibited by type-I IFN. Therefore, it was 
hypothesized that the influenza virus infection will inhibit the IL-23 pathway in vivo by a 
mechanism that does is not mediated by type-I IFN. It was also, hypothesized that this 
inhibition will result in downregulation of IL-17 that is secreted by Th17 cells. In order to 
test these hypotheses, respiratory IL-23 and IL-17 induction was determined by analyzing 
the expression of IL23p19 and IL-17A mRNA in the BAL cells of mice from different 
treatment groups as described in the materials and methods section of this chapter. 
Expression of IL23p19 was highest in the mice co-infected with S. ze and delNS1 and it 
differed significantly from the mice co-infected S. ze and PR8 virus (Fig 4.6, P<0.0001). 
Likewise, IL-17A expression was also highest in the S. ze and delNS1 virus-infected mice, 
and it was significantly different as compared to the S. ze and PR8 virus co-infected group 
(Fig 4.7, P<0.0001). However, contrary to in vitro results, there was no significant 
difference in the expression of IFN-β between the S. ze and delNS1 virus co-infected group 
and S. ze and PR8 virus infected groups (Fig 4.8). Moreover, induction of IFN-β was 
minimal in all the treatment groups, and it was lowest in the delNS1 virus alone-infected 
group. 
4.4. Discussion  
 The IL-23/IL-17 pathway has been shown to play a critical role in the clearance of 
secondary bacterial infection during influenza. However, viral and host factors involved in 
the modulation of the IL23/IL-17 pathway during influenza are poorly understood. In a 
recent study Kudva et al., suggested that influenza virus mediated induction of type-I IFN, 
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especially IFN-β, is responsible for the downregulation of IL-23/IL-17 pathway [300]. 
However, influenza viruses are known to suppress type-I interferons in infected cells. 
Therefore, presence of an interferon independent mechanism to downregulate the IL-23/IL-
17 pathway was speculated. CHOP-10, an ER stress-induced transcription factor, was 
found to be critical in the regulation of IL-23 [4], and current study suggested that NS1 
inhibits the expression of CHOP-10 (Chapter III). Thus, it was hypothesized that influenza 
virus NS1 protein-mediated inhibition of an ER stress-induced transcription factor CHOP-
10 causes downregulation of IL23/IL17 pathway. The hypothesis was tested in vitro using 
murine macrophage cell line (RAW cells) as well as in murine primary AM cells and 
subsequently confirmed in vivo using a mouse model. 
 Relative mRNA expression of IFN-β, IL-23p19 and CHOP-10 in the delNS1 virus-
infected and PR8 virus-infected RAW cells as well as in primary macrophages was 
analyzed. As expected, in both cell types delNS1 virus resulted in significantly higher 
expression of IFN-β suggesting that influenza virus NS1 inhibits the expression of type–I 
IFN. This finding is in corroboration with previously reported inhibitory effects of NS1 on 
the induction of type-I IFN [172, 175, 273, 358]. Next, in order to test if IFN-β has any 
inhibitory effect on IL-23, mRNA expression of IL-23p19 was investigated in the 
experimentally treated cells as above. As expected, delNS1 virus infection, as compared to 
the PR8 virus infection, resulted in significant upregulation of IL23p19 in both the 
macrophage types tested. While studying the effect of influenza virus on DC maturation, 
significantly higher induction of both type-I interferon and IL-23p19 was also observed in 
delNS1 virus infected cells as compared to the PR8 virus infected cells [274].  In the 
previous study (Chapter III), it was observed that NS1, at least in part, was responsible for 
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the inhibition of CHOP-10 in RAW cells. Those observations held true in the present study 
as well. DelNS1 virus, as compared to the PR8 virus, induced significantly higher 
expression of CHOP-10 in the RAW cells as well as in the primary alveolar macrophages. 
Taken together these results support the possibility of the existence of a type-I interferon 
independent mechanism that may involve CHOP-10.  
 Next, the effect of siRNA-mediated knock-down of CHOP-10 was investigated in 
cells infected with delNS1 virus. The underlying hypothesis was that the CHOP-10 
knockdown will lead to downregulation of delNS1 virus-induced IL-23p19 expression. 
Results of this experiment supported the hypothesis that a CHOP-10 knock down caused 
downregulation of IL-23p19 expression. My findings are in agreement with the previous 
reports on the effect of CHOP-10 knockdown on IL23p19 expression. CHOP-10 
knockdown in U937 cells, a human monocytic cell line, resulted in a substantial reduction 
in the TG/LPS induced IL-23p19 expression as well as in response to Chlamydia 
trachomatis infection [4]. Further, overexpression of CHOP-10 rescued, at least partially, 
the IL23p19 expression in the PR8 virus infected cells. These results implied that CHOP-
10, at least in part, is responsible for influenza virus NS1 mediated down-regulation of IL-
23p19.  
 Results of in vivo experiments in mice further confirmed the primary hypothesis 
and co-infection of bacteria and PR8 virus resulted in significant lower IL-23 and IL-17 as 
compared to the delNS1virus infected cells. Similar inhibition of bacteria-induced IL-17 
was observed when influenza virus-infected mice were superinfected with Streptococcus 
pneumoniae [359]. Unexpectedly, although lower than the S. Ze alone infected animals, 
mice infected with PR8 virus showed higher expression of IL23p19 and IL-17A as 
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compared to the delNS1 alone infected mice. A possible explanation could be that delNS1 
virus replicate poorly in the type-I interferon competent cells [276] and bacterial co-
infection results in the increased replication of the virus. Increased replication of the virus 
was observed in the combined S. aureus and influenza infection possibly due to enhanced 
cleavage of viral HA1 by streptococcal proteases [360].  Proteases derived from S. aureus 
and concentrated in vitro can cleave the HA, supporting the hypothesis [361]. 
 Unlike in vitro observations, IFN-β expression was lower in the delNS1 virus 
infected mice. Also, while mice co-infected with delNS1 and bacteria showed a significant 
difference in the induction of IFN-β, the induction was minimal in the all the treatment 
groups relative to the control group. These results are intriguing and do not exclude the 
role of type-I interferon in the influenza virus mediated subversion of IL23/IL17 pathway 
as reported previously by Kudva et al., [300]. A possible explanation for the minimal 
induction in virus infected mice could be that viral replication in the lung was not sufficient 
to induce substantial IFN-β. It is also possible that IFN-β induction is time and dose 
dependent. In the mouse model, it has been observed that while mutant viruses lacking 
NS1 induce IFN-β early that peaks around 24 hrs, wild type virus does not induce 
substantial levels of IFN-β during the first 24 hrs [362, 363]. Additionally, the difference 
in the source of type-I IFN in lungs of mice infected with PR8 virus and delNS1 could also 
contribute to our observation. Kallfass et al., reported that, while the primary source of 
IFN-β in IAV lacking NS1 was infected epithelial cells and CD11c- macrophage cells, in 
the lungs of mice infected with wild type virus , IFN-β was mainly produced from CD11c+ 
cells and the contribution of epithelial cells was minimal [363]. Since mice were infected 
under anesthesia, it is possible that most of the inoculum was deposited in the lungs and 
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hence there was not much contribution from the epithelial cells. However, studying the 
effect of time and dose of viruses on the kinetics of IFN-β induction in vivo could provide 
better insight and needs to be investigated further.  
 Although, there are certain limitations and, some areas need further investigation, 
results from this study support the hypothesis that influenza virus NS1 mediated  inhibition 
of CHOP-10 leads to the inhibition of respiratory  IL-23/IL17 axis of  innate immune 
response. However, the present study does not exclude the possible role of type-I IFN in 
the regulation of IL-23/IL17 pathway during influenza infection.   
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Table 4.1: List of Taqman® assays used in this study 
 
 
 
 
 
 
 
 
 
 
  
Target Gene aliases Taqman ®Assay ID 
CHOP-10 DDIT3, Gadd153 Mm01135937_g1 
IFN-β IFNb1 Mm00439552_s1 
IL-23p19 IL-23a Mm01160011_g1 
IL-17 IL-17A Mm00439618_m1 
GAPDH GAPD Mm99999915_g1 
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Figure 4.1: Relative expression of type-I interferon mRNA in macrophage cells  
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with 
Thapsigargin (0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A 
virus strain PR/8/34; delNS1: Influenza A virus isogenic to PR8 but lacks NS1 
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Figure 4. 2: Relative expression of IL-23p19 mRNA in macrophage cells 
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with 
Thapsigargin (0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A 
virus strain PR/8/34; delNS1: Influenza A virus isogenic to PR8 but lacks NS1 
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Figure 4.3: Relative expression of CHOP-10 mRNA in macrophage cells 
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with Thapsigargin 
(0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A virus strain PR/8/34; 
delNS1: Influenza A virus isogenic to PR8 but lacks NS1 
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Figure 4.4: Effect of CHOP-10 overexpression on IL-23p19 mRNA expression 
 
pCHOP-10+Mock: cells transfected with CHOP-10 overexpression plasmid then mock infected 
pCHOP-10+PR8: cells transfected with CHOP-10 overexpression plasmid then infected with PR8 
virus 
pCMV+PR8: cells transfected with empty control vector then infected with PR8 virus 
pCMV+Mock: cells transfected with empty control vector then mock infected  
**= p<0.001; ***= P<0.0001 
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Figure 4.5: Effect of CHOP-10 knockdown on IL-23p19 mRNA expression 
 
RAW+delNS1: Non-transduced RAW cells infected with delNS1 
CHOP-10-siRNA+delNS1: cells transduced with CHOP-10 siRNA lentivirus then infected with 
delNS1 virus 
Sic+delNS1 cells transduced with non-target control siRNA lentivirus then infected with delNS1 virus 
*=P<0.05; **=P<0.001 
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Figure 4.6: Relative expression of IL23p19 mRNA in mouse lung 
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or 
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and Zoo+PR8). 
cDNA was prepared from RNA extracted  from BAL cells and Real-time PCR was 
performed. Relative quantitation was done Δ ΔCT method. 
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Figure 4.7: Relative expression of IL-17A mRNA in mouse lung 
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or 
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and Zoo+PR8). 
cDNA was prepared from RNA extracted  from BAL cells and Real-time PCR was 
performed. Relative quantitation was done Δ ΔCT method. 
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Figure 4.8: Relative expression of IFN-β mRNA in mouse lung 
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or 
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and 
Zoo+PR8). cDNA was prepared from RNA extracted  from BAL cells and Real-time PCR 
was performed. Relative quantitation was done Δ ΔCT method. 
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CHAPTER 5 
Intranasal administration of recombinant IL-23 protects mice from lethal co-
infection of influenza A and Streptococcus zooepidemicus co-infection 
5.1. Introduction 
 Influenza A virus (IAV) infection is one of the major respiratory disease worldwide. 
Although, some IAV are sufficiently virulent to cause mortality in the host, secondary 
bacterial infections appear to be major contributors in the influenza associated deaths. 
During the influenza pandemic of 1918 that caused the death of about 40 to 50 million 
persons [214] while viral pneumonia killed many healthy young persons, most of the deaths 
were due to secondary bacterial pneumonia [225]. Bacterial infection during influenza 
virus infection can be either concurrent with the virus infection or subsequent to influenza 
virus infection. Concurrent bacterial and influenza pneumonia, although less frequent, have 
a worse outcome than sequential infection [364]. Concurrent influenza virus/bacterial 
infection is multifactorial and involves interaction between the host, bacteria and virus, 
whereas post-influenza infection involves interaction between host and bacteria only. 
Therefore, in post-influenza pneumonia the host response will be against bacterial 
pathogens only, but in concurrent infection the host will respond to the virus as well as the 
bacterial pathogen. These differences could affect the outcome and are important in 
deciding the therapeutic regimen for treating influenza pneumonia [207]. 
 Vaccination against seasonal influenza has been shown to reduce influenza 
incidences greatly.  Epidemics of seasonal influenza have been attributed to random single 
point mutations. Current advances in surveillance and epidemiological modeling could 
help in predicting these vaccine strains and allow satisfactory vaccine design in advance. 
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However, pandemic strains of IAV arise due to genetic shifts and therefore difficult to 
predict. Hence, effective therapeutic interventions remain important especially to prevent 
secondary bacterial complication, which is a major contributor in pandemic deaths. 
Antibiotics, as well as antiviral, have been used with limited success. Despite the 
availability of antibiotics, bacterial pneumonia was involved in almost two-thirds of fatal 
cases during the influenza pandemic of 1957. Inhibitors of viral replication have also been 
investigated. Neuraminidase inhibitors significantly improved the survival of mouse form 
pneumonia following influenza [365]. There is a relatively small window, however, in 
which neuraminidase inhibitors can reduce viral replication and missing that time-window 
will result in failure to prevent mortality in mice with influenza complicated by bacterial 
pneumonia [366]. Survival of mice with post-influenza bacterial pneumonia did not 
improve after treatment with Rimantadine [256]. Moreover, efficacy of these inhibitors in 
concurrent influenza and bacterial infection has not been investigated. Development of 
antibiotic resistant bacteria and antiviral-resistant influenza viruses further limit the use of 
these therapeutics. 
 A classical explanation for increased secondary bacterial infection during influenza 
has been the mechanical damage to the respiratory tract. However, altered host respiratory 
innate immune response has begun to be appreciated. Cytokines are an integral part of the 
host innate immune system, a broadly reactive defense mechanism of the host, which acts 
as the first line of defense against a variety of invading pathogens. IL-23 is a recently 
identified cytokine that has been shown to be important in the respiratory innate immune 
response. IL-23, in concert with IL-17, constitutes a newly identified innate immune 
pathway. The host IL-23/IL-17 pathway has been shown to play a critical role in the 
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clearance of many respiratory bacterial pathogens. However, its role during influenza and 
bacterial co-infection has not been investigated much. Thus, it was hypothesized that 
inhibition of respiratory IL23/IL17 pathway by influenza virus predisposes the host for 
secondary bacterial infection and restoring the respiratory IL-23 by rIL-23 administration 
will increase the clearance of bacteria and reduce the pathogenesis of influenza. In order to 
test this hypothesis, effect of restoration of respiratory IL-23 by intranasal administration 
was studied in a mouse model of concurrent influenza and bacterial infection. To study the 
effect of IL-23 restoration on clearance of virus and bacteria, weight loss of the animals 
and survival analysis was performed.  
5.2. Materials and methods 
Infectious agents: PR/8/34 strain (PR8) of IAV and an isogenic recombinant virus lacking 
NS1 (delNS1) as described in the previous chapters (chapter III) were used in the current 
study. For bacterial co-infection S.ze strain 7e was used. Bacteria were cultured and 
inoculum was prepared as described in chapter IV.  
Animals: Six-eight week old female CD-1 mice were purchased from a commercial 
supplier (Harlan). On arrival mice were housed in microisolater cages with an ad libitum 
supply of food and water. Mice were acclimatized for one week before infection and 
examined daily for any signs of stress or illness following the guidelines of Institutional 
Animal Care and Use Committee (IACUC) at University of Kentucky (fig 5.4, table 5.1). 
All the animal work was approved by IACUC at University of Kentucky. 
Inoculation of mice and rIL-23 administration: Mice were sedated with 
ketamine/xylazine administered by intraperitoneal injection. Once sedated mice were held 
upright by holding from the loose scruff at the neck. Inoculum was prepared to contain 
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approximately 1x106 CFU of bacteria and 1000 TCID50 units of PR8 virus in a final 
volume of 60µL normal saline. A small drop of inoculum was placed near each nostril so 
that mice involuntarily inhaled the inoculum. The inoculum was instilled from alternating 
the nostrils so that whole inoculum (60µL) was divided equally between two nostrils. Mice 
(n=18/group) were then assigned randomly to either rIL-23 or vehicle group that received 
PBS that was used to resuspended IL-23. Immediately after the viral/bacterial inoculation, 
a total of 3 µg rIL-23 in 20µl PBS was administered intranasally to the rIL-23 treatment 
group and 20µL PBS was administered intranasally to the vehicle only group as described 
for the inoculum. Investigator was blinded for which group received which treatment until 
data were collected and analysis was completed.  
BAL Fluid collection: Mice were euthanized 72 hrs post infection and BAL fluid was 
collected aseptically with sterile intra-tracheal catheterization as described in chapter IV. 
A total of 1 mL sterile normal saline was instilled in the lungs and aspirated. The aspirated 
fluid was re-infused and aspirated for a total of three times. BAL fluid was centrifuged at 
600g/5min and cell-free BAL was transferred to sterile microcentrifuge tubes as single use 
aliquots and frozen at -80○C.  
Determination of bacterial and viral load in the lungs: Lung bacterial and viral burden 
was determined from the BAL fluid of co-infected mice. In order to determine the bacterial 
burden, 10 fold serial dilutions of cell free BAL fluid were plated in duplicate onto 
Columbia CNA agar supplemented with 5% horse blood. Plates were incubated at 
37○C/5% CO2 for 24 hrs before counting the number of colonies and recording the results 
as CFU/mL. 
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 Lung virus titer was determined by IAV matrix gene-based quantitative real-time 
PCR. Viral RNA was extracted from 50ul cell-free BAL fluid using the magmax™ 96 viral 
nucleic acid extraction kit (Ambion AM-1836) following manufacturers instruction. 
Quantitative real-time PCR was performed using 1-step RT-PCR kit on ABI 7500 platform 
using the primer probes described previously (CDC REF #I-007-05). Sequence of primer 
and probes is provided in Table 5.2.  
Data analysis: Pathogen burden and weight loss data was analyzed using students T-test 
with Welch’s correction using GraphPad (Prism6) statistical software. Survival fractions 
of the two groups were estimated using Kaplan-Meier method and survival curves were 
compared by log-Rank (Mentel-Cox) test and Gehan-Breslaw-Wilcoxon test using 
GraphPad statistical software (Prism6).  
5.3. Results 
Effect of IL-23 administration on bacterial and viral burden in the lungs of ci-infected 
mice: Mice were observed daily for clinical signs and scored following the guidelines 
provided by IACUC (Table 5.1 and Fig. 5.4). Pronounced clinical signs of disease 
characterized by ruffled fur, lethargy, hunched posture and labored breathing were 
displayed by both the treatment groups of mice as early as day 2. However, subsequent 
clinical signs were more pronounced in the vehicle only group and some of the mice in 
rIL-23 treatment group started to recover by day 6 onwards.  
 Since IL-23 treated mice showed less severe clinical signs as compared to the 
vehicle only treated mice, it was hypothesized that treated mice would have improved 
clearance of bacteria and virus from the lungs. As mortality started on day three PI, we 
chose 72 hrs PI time point to assess the bacterial and viral burden in the two groups.  Results 
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of bacterial load in the BAL fluid are presented in Fig 5.1. Although statistically non-
significant (P=0.5490), bacterial count in the IL-23 treated mice trended towards lower 
side as compared to the non-treated mice suggesting that IL-23 might have a role in the 
clearance of bacteria. 
 Viral burden was determined in the cell free BAL fluid by using quantitative real-
time PCR. Results of the quantitative real-time PCR (Fig 5.1B) are presented as threshold 
cycle (CT) value. There was no statistically significant difference in viral load between two 
groups (P=0.3066), suggesting that IL-23 had no effect on viral clearance.  
Effect of intranasal rIL-23 treatment on weight loss in co-infected mice: In order to 
determine whether IL-23 could affect the clinical outcome of the co-infection, we 
compared the weight loss of the treated and non-treated mice. Weight of each mouse was 
recorded every 24 hrs and percent weight loss was calculated respective to weight on day 
zero. Mice with a weight loss of ≥ 25% of day zero weight were euthanized and considered 
dead for data analysis purposes. Mean percent weight loss of mice from each group are 
presented in Fig 5.2. As expected, mice treated with PBS (vehicle), as compared to the rIL-
23 treated mice, showed higher weight loss. Weight loss was statistically significant as 
early as day two (p=0.0005), and by day six all the mice were dead in the non-treated 
vehicle group. 
Effect IL-23 treatment on survival of co-infected mice: Next we wanted to determine 
whether intranasal rIL-23 treatment affects the survival of mice. Age and sex matched 6-8 
week old mice were randomly allotted to either rIL-23 treated group or a control group 
treated with vehicle only (PBS).  Each mouse of both the group was observed daily and 
clinical scores were recorded as per the IACUC guidelines (Table 5.1). Any mouse 
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showing a cumulative score of ≥6 or a score of three on a single category was euthanized 
(IACUC guideline, Fig 5.4) and considered dead for data analysis purposes. Also, any 
mouse showing ≥ 25% of weight loss of day zero weight was euthanized and considered 
dead for data analysis purpose. Results of mortality are presented in Fig 5.3. First death 
was observed in the rIL-23 treated group on day 3. However, later on mortality was more 
pronounced in non-treated group and by day 6, all the mice in non-treated group were 
succumbed to death. On the other hand, 50% (9/18) of the rIL-23 treated mice were 
surviving on day 6. Most of the surviving mice either did not show any further weight loss 
or showed a minimal weight loss suggesting recovery. Survival curve analysis showed a 
highly significant difference with a p-value of 0.0015 and 0.0069 in Log-rank (Mentel-
cox) and Gehan-Breslaw-Wilcoxon tests, respectively, and the mean death time in the 
treated group was prolonged by 1 day. 
5.4. Discussion 
 Influenza infection is a leading cause of death worldwide. However, most of the 
deaths associated with influenza have been ascribed to the secondary bacterial infection. 
Secondary bacterial infection associated with influenza may either be due to concurrent 
infection or follow a preceding influenza infection. As bacterial pneumonia often ensues 
3-7 day post-influenza infection, most of the studies have used a sequential model of 
secondary bacterial infection where bacterial inoculations were performed up to seven days 
after preceding influenza challenge. However, although less frequent, concurrent influenza 
and bacterial infections involve more complex interactions of host, virus, and bacteria than 
the sequential infection and often result in more serious outcome than sequential infection 
[364]. Furthermore, some of the secondary bacterial invaders during influenza infection 
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are opportunistic pathogens commonly present in the upper respiratory tract of humans as 
well as animals which could lead to secondary infection during influenza. Therefore, in the 
current study a concurrent infection model was used to investigate the therapeutic potential 
of rIL-23 on influenza-associated secondary bacterial infections. Since S. zoo is a 
commonly associated secondary invader during equine influenza, the overreaching goal of 
the study was to investigate the effect of rIL-23 supplementation on outcome secondary S. 
zoo infection during equine influenza infection. However, recombinant equine IL-23 is not 
available yet, therefore, we tested our hypothesis in the mouse model. Mouse has been 
successfully used as a model for S. zoo by Dr. P Timoney at Gluck equine research center. 
Furthermore, the PR8 strain of influenza virus is well adapted to the mouse model and has 
been used extensively to study the pathogenesis and immune response against influenza.  
 IL-23 is a recently identified member of IL-6 family of cytokines that is important 
in the induction and maintenance of Th17 cells that secrete IL-17. IL-17 is an early 
proinflammatory cytokine that mediates host defense against several respiratory bacterial 
pathogens. Although there are reports on using intranasal rIL-23 as a therapeutic 
intervention against respiratory bacterial infections, it has not been investigated much 
during influenza and bacterial co-infection. There is only one study that investigated the 
effect of restoration of IL23 in the lungs of influenza and bacterial co-infection in which 
Adenovirus expressing rIL-23 was found to improve the clearance of bacteria in S. 
pneumoniae and influenza co-infected mice [300].  Thus, current study appears to be the 
first to utilize intranasal rIL-23 as therapeutic intervention during concurrent influenza and 
bacterial co-infection.  
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 The hypothesis in the current study was that rIL-23 treatment will improve the 
clearance of virus and bacteria. Unexpectedly, there was no significant difference between 
respiratory viral load between rIL-23 and control animals. Likewise, although bacterial 
counts were lower in the treated mice, they were statistically not significant. In contrast to 
the present study, Kudva et al., observed that overexpression of IL-23 in the lungs of mice 
resulted in improved clearance of virus as well as bacteria [300]. It should be noted, 
however, that authors in that study used a sequential model of infection where bacterial 
infection was performed at day six post-influenza infection. It is possible that during this 
time there was already some repair of the tissue damage caused by influenza virus resulting 
in decreased adherence of bacteria. Additionally, since adenovirus was used to express the 
IL-23, it would be difficult to determine the exact level of IL-23 in the lungs. Furthermore, 
timing and duration of the IL-23 administration may have important implications on the 
outcome. One of the limitations of the present study is that only a single intranasal dose of 
rIL-23 concurrent with the infection was used. In the case of adenoviral overexpression 
levels of IL-23 could be maintained during the infection and may have a significant effect 
on the clearance of virus as well as bacteria. It is possible that a subsequent dose may help 
in maintaining the levels of IL-23 in the lungs and further improve the clearance of virus 
and bacteria and needs to be investigated. 
 As expected, rIL-23 treated mice, as compared to the vehicle only treated mice, 
showed less severe signs of disease, less weight loss and improved survival suggesting that 
intranasal rIL-23 could limit the pathology of co-infection. One possible mechanism could 
be the suppression of the early strong inflammatory response (cytokine storm) that plays 
an important role in the pathogenesis of influenza. It was recently found that adenovirus-
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mediated overexpression of IL-23 resulted in the decreased lung inflammation in influenza 
and S. pneumoniae co-infected mice [300]. Additionally, improved survival of rIL-23 
treated mice could also be due to increased tolerance of the host for infection due to 
accelerated tissue repair and homeostasis. Recently, it was observed that, despite normal 
anti-bacterial immune response, hosts were susceptible to lethal secondary bacterial 
infection in influenza infected mice due to impaired ability to tolerate respiratory tissue 
damage [102]. Studies with amphiregulin, a member of the family of epithelial growth 
factors, revealed an important role in lung tissue homeostasis in the survival of influenza 
and bacteria co-infected mice. While amphiregulin treatment did not affect the bacterial 
and viral burden in co-infected mice, it resulted in decreased lung tissue damage and 
significantly improved weight loss and the survival of co-infected mice [102]. IL-23 could 
help in the repair of damaged respiratory tissue mediated by IL-22. IL-22 is important for 
the modulation of tissue responses during inflammation, and it induces proliferative and 
anti-apoptotic pathways, as well as anti-microbial molecules that help prevent tissue 
damage and aid in its repair [367]. IL-23 has been shown to be critical in the differentiation 
and proliferation of Th17 cells [368].  Also, IL-22 has been reported to be robustly secreted 
by Th17 cells in IL-23 dependent fashion [369]. Although the extent of tissue damage was 
not evaluated between IL-23 treated and control groups and needs to be investigated, it 
seems plausible that the difference in tissue repair could have resulted in improved 
tolerance in the rIL-23 treated mice.  
 In the present study we observed that while IL-23, to some degree, helped in 
clearance of bacteria in co-infected mice, it did not affect the viral clearance. Although, we 
did not establish the underlying mechanism, we did observe that intranasal rIL-23 
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administration, significantly improved the survival of co-infected mice. From our study, 
we conclude that intranasal administration of rIL-23 has a beneficial effect during 
concurrent bacterial and influenza virus co-infection and in the wake of emerging drug 
resistant influenza viruses and bacteria, IL-23 could potentially be included as alternative 
therapeutic intervention.  
 
 
 
1
0
5
 
 
Figure 5.1: Bacterial and viral burden in the lungs of influenza and S. ze co-infected mice 
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation 
mice were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). At 72 hr PI BAL fluid was 
collected.Cell free BAL fluid was plated on CAN agar supplemented with 5% horse blood and colonies 
were counted after 24 hr and bacterial burden (CFU/mL of BAL fluid) was determined (A). viral RNA 
was extracted from cell free BAL fluid and Real-Time PCR CT values were used to compare the viral 
burden.  
A B 
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Figure 5.2: Effect of intranasal rIL-23 administration on weight loss in influenza and S. ze co-infected 
mice  
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation mice 
were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). Mice were weighed daily and weight 
loss was calculated to as percent of day 0 weight. Data was analyzed by using t-test with Welch’s correction 
using GraphPad Prism 6 software. (*= P<0.05; **= P<0.01; ***=P<0.0001) 
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Figure 5.3: Effect of intranasal rIL-23 administration on survival of influenza and S. ze co-infected 
mice 
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation 
mice were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). Mortality was recorded 
andsurvival fractions were calculated. Survival curve comparison was performed using Prism 6.0 
(GraphPad software) that uses Kaplan-Meier method to generate survival fractions and survival curves 
are compared by log-Rank (Mentel-Cox) test and Gehan-Breslaw-Wilcoxon test. Two curves were 
significantly different with P value 0.0015 and 0.0069 in Log-rank (Mentel-cox) and Gehan-Breslaw-
Wilcoxon tests, respectively. 
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Score 0 for a category Total score 1-6 and <3 for a single 
category 
Score 3 for a single category 
or in multiple categories 
No Intervention 
Check daily 
No Intervention 
Recheck in 6-12 hours 
Euthanasia 
Pain/Stress Score 
Figure 5.4: Treatment flow chart for mice with respiratory infections  
From (IACUC, University of Kentucky) 
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Table 5.1: Clinical scoring criteria for mice 
 
Criteria/Score 0 1 2 3 Total 
Locomotion Moving normally 
around cage, not 
hugging the sides of 
the cage. 
Stumbling , falling, or 
hugging the sides of 
the cage. 
Writhing, 
stumbling and/or 
falling. OR 
Movement only 
when stimulated. 
No movement.  
Respiration Normal rate with no 
audible respiratory 
sounds to naked ear 
Mild “chattering” or 
“snoring” 
Moderate 
“chattering” or 
“snoring” 
Labored 
breathing , 
increased 
respiratory rate  
 
Behavior Normal cage 
exploration, normal 
food and water 
consumption, animal 
calm in cage. 
Previously social 
animal still social. 
Minimal exploration, 
increased or 
decreased food and/or 
water consumption. 
Previously social 
animal has become 
withdrawn or 
aggressive. 
No cage 
exploration, 
hunched posture, 
anorexic for 24 hrs. 
No cage 
exploration, 
hunched 
posture, 
piloerection, 
anorexic, or 
moribund 
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Table 5.2: Primer and probe sequence for influenza virus real-time PCR 
 
 
 
 
 
 
 
 
 
 
 
 
Primer/probe Sequence (5’>3’) Target IAV gene Final Concentration 
InfA Forward GAC CRA TCC TGT CAC CTC TGA 
C 
Matrix (M1) 800nM 
InfA Reverse AGG GCA TTY TGG ACA AAK CGT 
CTA 
Matrix (M1) 800nM 
InfA Probe FAM-TGC AGT CCT CGC TCA CTG 
GGC ACG-BHQ1 
Matrix (M1) 200nM 
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 CHAPTER 6  
General discussion and conclusions 
 The goal of the present study was to identify the possible viral and host factors that 
predispose the host to secondary bacterial infection during influenza virus infection. The 
major hypothesis was that influenza virus NS1 protein-mediated inhibition of an ER stress 
transcription factor mediates the inhibition of the respiratory IL-23/IL17 axis of innate 
immune response. I tested my hypothesis in vitro using mouse macrophage cell line as well 
as primary alveolar macrophage cells and in vivo using mouse model. Although, there are 
certain areas that need to be further investigated, results from the study support our 
hypothesis. 
 In the first part of the study, effect of NS1 protein on ER stress response of mouse 
macrophages was studied in vitro. Results of this study support the hypothesis that 
influenza virus NS1 mediates differential activation of the ER stress response. While 
influenza virus induced activation of chaperones, it inhibited the induction of CHOP-10. 
Since influenza viruses rely heavily on the host cellular machinery for their protein 
synthesis, it appears counterintuitive that virus would not induce ER stress.  
 Why would influenza virus inhibit ER stress? ER stress response is an evolutionary 
conserved host response that is used to resolve the excessive protein load on the ER. By 
activating three arms of UPR, the host cell tries to restore the ER homeostasis. It seems 
that influenza virus cleverly inhibits the PERK and IRE1 branches, but does not inhibit the 
ATF6 branch. While activation of PERK leads to the EIF2α phosphorylation that shuts 
down the global protein synthesis, activation of IRE1 branch leads to induction of 
transcription factors involved in the ER-associated degradation. Thus, activation of these 
 
112 
 
branches would limit the viral protein synthesis. Additionally, EIF2α phosphorylation 
leads to selective transcription of ATF4 that induces CHOP-10, a pro-apoptotic factor 
induced during the ER stress. While apoptosis may help in the viral spread and 
pathogenesis, premature cellular death would be detrimental for virus replication.The 
ATF6 branch activates transcription of ER chaperones that could promote viral replication 
by increasing the folding capacity of the ER. Indeed, ER chaperone protein Erp57 is 
reported to be crucial in the folding of influenza virus HA [315]. Therefore, the differential 
activation of the UPR pathway by influenza virus in the present study would support 
influenza viral replication.  
 Recently, a type-I IFN mediated mechanism for IL-23 inhibition has been reported, 
but influenza virus is known to inhibit type-I IFN. So, an interferon independent 
mechanism was speculated. The hypothesis was that influenza virus NS1 protein-mediated 
inhibition of CHOP-10 results in the inhibition of IL-23 expression. The hypothesis was 
tested in vitro in mouse macrophage cells and in vivo using a mouse model. Although in 
vivo results in the present study could not exclude the possibility of type-I IFN dependent 
mechanism, results from the in vitro study do suggest the presence of type-I interferon 
independent mechanism mediated by CHOP-10. Recent findings of the critical role of 
CHOP-10 in IL-23 regulation in human dendritic cells [4], further support our hypothesis.  
 Innate immune responses are mainly triggered by the PRRs. Then why would ER 
stress influence the innate immune response? PRR act as sentinels to sense the 
environmental danger signals such as extracellular microbial products and products of 
stressed or damaged tissues such as PGE2, ATP and urate [370]. Similar to the PRR, 
activation of UPR may serve as a counterpart to the external danger signal detection system 
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especially in the case of intracellular pathogens such as virus and intracellular bacteria. By 
activating UPR, cell may sense the presence of intracellular pathogens. Thus, integrating 
the PRR signaling with UPR activation would favor a failsafe mechanism for the host to 
detect danger signals especially in the case of intracellular pathogens. 
 Why would ER stress signal induce IL-23?  In a review of IL-23 and IL-17 immune 
pathway, Mckenzie et al., [370] suggested that IL-23 is critical in driving the early immune 
response to infection. IL-23 rapidly induces IL-17 from Th17 cells that allow early 
recruitment of phagocytic cells such as neutrophils and macrophages to provide early 
clearance of pathogens [370]. Therefore, inhibition of the respiratory IL-23/IL-17 response 
could be important for the replication and pathogenesis of influenza.  
 Having found that influenza virus inhibits the IL23/IL17 pathway, it was speculated 
that restoration of IL-23 in the lungs would reduce the pathogenesis of influenza virus 
infection. Secondary bacterial infections are common during influenza, and IL-23 has been 
shown to provide protection from a variety of respiratory bacterial pathogens. Therefore, 
the hypothesis was that the restoration of respiratory IL-23/IL-17 innate immune pathway 
in the lungs would help in clearance of the pathogens and protect the host from lethal co-
infection of influenza and bacteria. In order to test this hypothesis, intranasal rIL-23 
administration was used to restore the respiratory IL-23/IL-17 pathway in a mouse model 
of concurrent influenza and bacterial infection. Although, rIL-23 administration had no 
effect on viral clearance, it did help in the clearance of bacteria, albeit to a limited extent. 
However, a notable finding was that a single dose of intranasal IL-23 significantly 
improved the survival of co-infected infected mice. 
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 How could rIL-23 administration protect the host without significantly affecting 
the pathogen clearance? Protection of the host can be achieved in three ways: avoidance, 
resistance, and tolerance [371]. While avoidance reduces the risk of exposure to infectious 
agents, resistance reduces pathogen burden once the infection is established [371]. On the 
other hand, tolerance increases the fitness of the host by reducing the negative impact of 
an infection without directly affecting the pathogen load [372-374]. It is possible that IL-
23, by inducing an additional mediator such as IL-22, induces a rapid tissue repair and 
could increase host tolerance. Indeed, recent findings by Jamieson et al., support this idea. 
They found that influenza virus infection enhanced susceptibility to secondary bacterial 
infection, even when bacterial infection was controlled by the immune system [102]. 
However, it should be noted that we have used a single intranasal dose of rIL-23, and we 
could not completely determine whether the protective effect of IL-23 was due to increased 
immune response or the tolerance.  
 Based on findings from current study and previously published reports, a working 
model for how influenza virus NS1-mediates inhibition of CHOP-10 and how this leads to 
inhibition of IL-23 and increases the susceptibility of the host to secondary bacterial 
infection has been presented in Fig 6.1.  
In conclusion, this dissertation demonstrates for the first time that influenza virus NS1 
protein is the viral factor that is involved in differential activation of cellular ER stress 
response. Additionally, this study also provides the evidence for the first time that influenza 
virus mediated inhibition of IL-23 is mediated by ER stress-induced transcription factor 
CHOP-10.The study also provides valuable insights on the increased susceptibility of 
bacterial infection during influenza that could be utilized for future therapeutic targets 
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against influenza virus. This study also shows that IL-23 could be used as potential 
therapeutic agent to reduce influenza-associated mortality. 
Limitations and future directions: This dissertation provide evidence to support the 
primary hypothesis that influenza virus NS1-mediated inhibition of CHOP-10 mediates the 
inhibition of IL-23/IL-17 pathway of respiratory innate immune response which results in 
enhanced bacterial susceptibility during influenza. However, the study did not identify the 
exact mechanism of inhibition and proposed mechanism is substantially built upon findings 
in different cell type. Therefore, future research needs to be done to confirm the proposed 
model in alveolar macrophages. In the current study, effect of single intranasal dose rIL-
23 administration on pathogen clearance was investigated in an immunocompetent host. 
To further delineate the role of IL-23 in protective immune response, future research using 
IL23 knockout host could further confirm the protective roles of IL-23. Also, 
characterization of innate immune cells, cytokines and tissue repair after IL-23 
administration would be useful in understanding the IL-23/IL-17 immunity against 
secondary bacterial infections during influenza infection.   
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Figure 6.1: Model for influenza virus NS1-mediated inhibition of IL-23 
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